<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39083202</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>21</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1869-1889</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>11</Issue><PubDate><Year>2024</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Science China. Life sciences</Title><ISOAbbreviation>Sci China Life Sci</ISOAbbreviation></Journal><ArticleTitle>COVID-19 vaccine updates for people under different conditions.</ArticleTitle><Pagination><StartPage>2323</StartPage><EndPage>2343</EndPage><MedlinePgn>2323-2343</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11427-024-2643-1</ELocationID><Abstract><AbstractText>SARS-CoV-2 has caused global waves of infection since December 2019 and continues to persist today. The emergence of SARS-CoV-2 variants with strong immune evasion capabilities has compromised the effectiveness of existing vaccines against breakthrough infections. Therefore, it is important to determine the best utilization strategies for different demographic groups given the variety of vaccine options available. In this review, we will discuss the protective efficacy of vaccines during different stages of the epidemic and emphasize the importance of timely updates to target prevalent variants, which can significantly improve immune protection. While it is recognized that vaccine effectiveness may be lower in certain populations such as the elderly, individuals with chronic comorbidities (e.g., diabetes with poor blood glucose control, those on maintenance dialysis), or those who are immunocompromised compared to the general population, administering multiple doses can result in a strong protective immune response that outweighs potential risks. However, caution should be exercised when considering vaccines that might trigger an intense immune response in populations prone to inflammatory flare or other complications. In conclusion, individuals with special conditions require enhanced and more effective immunization strategies to prevent infection or reinfection, as well as to avoid the potential development of long COVID.</AbstractText><CopyrightInformation>&#xa9; 2024. Science China Press.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Huang</LastName><ForeName>Yijiao</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>National Center for Respiratory Medicine; State Key Laboratory of Respiratory Health and Multimorbidity; National Clinical Research Center for Respiratory Diseases; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, 100029, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, 100029, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Basic Medical Sciences, Tsinghua Medicine, Tsinghua University, Beijing, 100084, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tsinghua University-Peking University Joint Centre for Life Sciences, Tsinghua University, Beijing, 100084, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Wang</LastName><ForeName>Weiyang</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>National Center for Respiratory Medicine; State Key Laboratory of Respiratory Health and Multimorbidity; National Clinical Research Center for Respiratory Diseases; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, 100029, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, 100029, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>National Center for Respiratory Medicine; State Key Laboratory of Respiratory Health and Multimorbidity; National Clinical Research Center for Respiratory Diseases; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, 100029, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, 100029, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Disease, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, 264000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Zai</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing, 100029, China. wzai_163pass@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Bin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>National Center for Respiratory Medicine; State Key Laboratory of Respiratory Health and Multimorbidity; National Clinical Research Center for Respiratory Diseases; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, 100029, China. caobin_ben@163.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, 100029, China. caobin_ben@163.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tsinghua University-Peking University Joint Centre for Life Sciences, Tsinghua University, Beijing, 100084, China. caobin_ben@163.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, 100730, China. caobin_ben@163.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Changping Laboratory, Beijing, 102200, China. caobin_ben@163.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Capital Medical University, Beijing, 100069, China. caobin_ben@163.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>New Cornerstone Science Laboratory, China-Japan Friendship Hospital, Beijing, 100029, China. caobin_ben@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Sci China Life Sci</MedlineTA><NlmUniqueID>101529880</NlmUniqueID><ISSNLinking>1674-7305</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000087507" MajorTopicYN="N">Vaccine Efficacy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016867" MajorTopicYN="N">Immunocompromised Host</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">elderly</Keyword><Keyword MajorTopicYN="N">immunocompromised</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword><Keyword MajorTopicYN="N">variants of concern</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>4</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>31</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>31</Day><Hour>11</Hour><Minute>9</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39083202</ArticleId><ArticleId IdType="doi">10.1007/s11427-024-2643-1</ArticleId><ArticleId IdType="pii">10.1007/s11427-024-2643-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abbasi, J. (2022). The COVID heart&#x2014;one year after SARS-CoV-2 infection, patients have an array of increased cardiovascular risks. JAMA 327, 1113&#x2013;1114.</Citation><ArticleIdList><ArticleId IdType="pubmed">35234824</ArticleId><ArticleId IdType="doi">10.1001/jama.2022.2411</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguilar-Bretones, M., Fouchier, R.A.M., Koopmans, M.P.G., and van Nierop, G.P. (2023). Impact of antigenic evolution and original antigenic sin on SARS-CoV-2 immunity. J Clin Invest 133, e162192.</Citation><ArticleIdList><ArticleId IdType="pubmed">36594464</ArticleId><ArticleId IdType="pmc">9797340</ArticleId><ArticleId IdType="doi">10.1172/JCI162192</ArticleId></ArticleIdList></Reference><Reference><Citation>Akpek, M. (2022). Does COVID-19 cause hypertension? Angiology 73, 682&#x2013;687.</Citation><ArticleIdList><ArticleId IdType="pubmed">34889662</ArticleId><ArticleId IdType="pmc">9260192</ArticleId><ArticleId IdType="doi">10.1177/00033197211053903</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Kaabi, N., Zhang, Y., Xia, S., Yang, Y., Al Qahtani, M.M., Abdulrazzaq, N., Al Nusair, M., Hassany, M., Jawad, J.S., Abdalla, J., et al. (2021). Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults. JAMA 326, 35&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">34037666</ArticleId><ArticleId IdType="doi">10.1001/jama.2021.8565</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander, J.L., Moran, G.W., Gaya, D.R., Raine, T., Hart, A., Kennedy, N.A., Lindsay, J.O., MacDonald, J., Segal, J.P., Sebastian, S., et al. (2021). SARS-CoV-2 vaccination for patients with inflammatory bowel disease: A British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement. Lancet Gastroenterol Hepatol 6, 218&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">33508241</ArticleId><ArticleId IdType="pmc">7834976</ArticleId><ArticleId IdType="doi">10.1016/S2468-1253(21)00024-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Allotey, J., Fernandez, S., Bonet, M., Staffings, E., Yap, M., Kew, T., Zhou, D., Coomar, D., Sheikh, J., Lawson, H., et al. (2020). Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: Living systematic review and meta-analysis. BMJ 370, m3320.</Citation><ArticleIdList><ArticleId IdType="pubmed">32873575</ArticleId><ArticleId IdType="doi">10.1136/bmj.m3320</ArticleId></ArticleIdList></Reference><Reference><Citation>Amanna, I.J., Carlson, N.E., and Slifka, M.K. (2007). Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 357, 1903&#x2013;1915.</Citation><ArticleIdList><ArticleId IdType="pubmed">17989383</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa066092</ArticleId></ArticleIdList></Reference><Reference><Citation>Ameratunga, R., Longhurst, H., Steele, R., Lehnert, K., Leung, E., Brooks, A.E.S., and Woon, S.T. (2021). Common variable immunodeficiency disorders, T-Cell responses to SARS-CoV-2 vaccines, and the risk of chronic COVID-19. J Allergy Clin Immunol-Pract 9, 3575&#x2013;3583.</Citation><ArticleIdList><ArticleId IdType="pubmed">34182162</ArticleId><ArticleId IdType="pmc">8230758</ArticleId><ArticleId IdType="doi">10.1016/j.jaip.2021.06.019</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreano, E., Paciello, I., Pierleoni, G., Piccini, G., Abbiento, V., Antonelli, G., Pileri, P., Manganaro, N., Pantano, E., Maccari, G., et al. (2023). B cell analyses after SARS-CoV-2 mRNA third vaccination reveals a hybrid immunity like antibody response. Nat Commun 14, 53.</Citation><ArticleIdList><ArticleId IdType="pubmed">36599850</ArticleId><ArticleId IdType="pmc">9811867</ArticleId><ArticleId IdType="doi">10.1038/s41467-022-35781-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Anjan, S., Natori, Y., Fernandez Betances, A.A., Agritelley, M.S., Mattiazzi, A., Arosemena, L., Andrews, D.M., Simkins, J., Guerra, G., and Abbo, L.M. (2021). Breakthrough COVID-19 infections after mRNA vaccination in solid organ transplant recipients in Miami, Florida. Transplantation 105, e139&#x2013;e141.</Citation><ArticleIdList><ArticleId IdType="pubmed">34319928</ArticleId><ArticleId IdType="pmc">8487698</ArticleId><ArticleId IdType="doi">10.1097/TP.0000000000003902</ArticleId></ArticleIdList></Reference><Reference><Citation>Anna R Yousaf, J.M., Gwynn L., Bloodworth, R., Rai, R., Jeddy, Z., LeClair, L.B., Edwards, L., Olsho, L.E.W., Newes-Adeyi, G., et al.. (2024). Correction to: 1935. COVID-19 mRNA vaccination reduces the occurrence of post-COVID conditions in U.S. children aged 5&#x2013;17 years following Omicron SARS-CoV-2 infection, July 2021-September 2022. Open Forum Infect Dis 11, ofae100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofae100</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli, M., Penfold, R.S., Canas, L.D.S., Sudre, C., Rjoob, K., Murray, B., Molteni, E., Kerfoot, E., Cheetham, N., Pujol, J.C., et al. (2023). SARS-CoV-2 infection following booster vaccination: illness and symptom profile in a prospective, observational community-based case-control study. J Infect 87, 506&#x2013;515.</Citation><ArticleIdList><ArticleId IdType="pubmed">37777159</ArticleId><ArticleId IdType="doi">10.1016/j.jinf.2023.08.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbel, R., Peretz, A., Sergienko, R., Friger, M., Beckenstein, T., Duskin-Bitan, H., Yaron, S., Hammerman, A., Bilenko, N., and Netzer, D. (2023). Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study. Lancet Infect Dis 23, 914&#x2013;921.</Citation><ArticleIdList><ArticleId IdType="pubmed">37062302</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(23)00122-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbel, R., Sergienko, R., Friger, M., Peretz, A., Beckenstein, T., Yaron, S., Netzer, D., and Hammerman, A. (2022). Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years. Nat Med 28, 1486&#x2013;1490.</Citation><ArticleIdList><ArticleId IdType="pubmed">35468276</ArticleId><ArticleId IdType="doi">10.1038/s41591-022-01832-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Arregoc&#xe9;s-Castillo, L., Fern&#xe1;ndez-Ni&#xf1;o, J., Rojas-Botero, M., Palacios-Clavijo, A., Galvis-Pedraza, M., Rinc&#xf3;n-Medrano, L., Pinto-&#xc1;lvarez, M., Ruiz-G&#xf3;mez, F., and Trejo-Valdivia, B. (2022). Effectiveness of COVID-19 vaccines in older adults in Colombia: a retrospective, population-based study of the ESPERANZA cohort. Lancet Healthy Longev 3, e242&#x2013;e252.</Citation><ArticleIdList><ArticleId IdType="pubmed">35340743</ArticleId><ArticleId IdType="pmc">8937302</ArticleId><ArticleId IdType="doi">10.1016/S2666-7568(22)00035-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Atchison, C.J., Davies, B., Cooper, E., Lound, A., Whitaker, M., Hampshire, A., Azor, A., Donnelly, C.A., Chadeau-Hyam, M., Cooke, G.S., et al. (2023). Long-term health impacts of COVID-19 among 242,712 adults in England. Nat Commun 14, 6588.</Citation><ArticleIdList><ArticleId IdType="pubmed">37875536</ArticleId><ArticleId IdType="pmc">10598213</ArticleId><ArticleId IdType="doi">10.1038/s41467-023-41879-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Aveyard, P., Gao, M., Lindson, N., Hartmann-Boyce, J., Watkinson, P., Young, D., Coupland, C.A.C., Tan, P.S., Clift, A.K., Harrison, D., et al. (2021). Association between pre-existing respiratory disease and its treatment, and severe COVID-19: a population cohort study. Lancet Respir Med 9, 909&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">33812494</ArticleId><ArticleId IdType="pmc">8016404</ArticleId><ArticleId IdType="doi">10.1016/S2213-2600(21)00095-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden, L.R., El Sahly, H.M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S.A., Rouphael, N., Creech, C.B., et al. (2021). Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 384, 403&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pubmed">33378609</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2035389</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee, A., Nasir, J.A., Budylowski, P., Yip, L., Aftanas, P., Christie, N., Ghalami, A., Baid, K., Raphenya, A.R., Hirota, J.A., et al. (2020). Isolation, sequence, infectivity, and replication kinetics of severe acute respiratory syndrome coronavirus 2. Emerg Infect Dis 26, 2054&#x2013;2063.</Citation><ArticleIdList><ArticleId IdType="pubmed">32558639</ArticleId><ArticleId IdType="pmc">7454076</ArticleId><ArticleId IdType="doi">10.3201/eid2609.201495</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartsch, Y.C., St. Denis, K.J., Kaplonek, P., Kang, J., Lam, E.C., Burns, M.D., Farkas, E. J., Davis, J.P., Boribong, B.P., Edlow, A.G., et al. (2022). SARS-CoV-2 mRNA vaccination elicits robust antibody responses in children. Sci Transl Med 14, eabn9237.</Citation><ArticleIdList><ArticleId IdType="pubmed">35881018</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.abn9237</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellamkonda, N., Lambe, U.P., Sawant, S., Nandi, S.S., Chakraborty, C., and Shukla, D. (2022). Immune response to SARS-CoV-2 vaccines. Biomedicines 10, 1464.</Citation><ArticleIdList><ArticleId IdType="pubmed">35884770</ArticleId><ArticleId IdType="pmc">9312515</ArticleId><ArticleId IdType="doi">10.3390/biomedicines10071464</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergman, P., Blennow, O., Hansson, L., Mielke, S., Nowak, P., Chen, P., S&#xf6;derdahl, G., &#xd6;sterborg, A., Smith, C.I.E., Wullimann, D., et al. (2021). Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial. eBioMedicine 74, 103705.</Citation><ArticleIdList><ArticleId IdType="pubmed">34861491</ArticleId><ArticleId IdType="pmc">8629680</ArticleId><ArticleId IdType="doi">10.1016/j.ebiom.2021.103705</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhaskaran, K., Rentsch, C.T., MacKenna, B., Schultze, A., Mehrkar, A., Bates, C.J., Eggo, R.M., Morton, C.E., Bacon, S.C.J., Inglesby, P., et al. (2021). HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform. Lancet HIV 8, e24&#x2013;e32.</Citation><ArticleIdList><ArticleId IdType="pubmed">33316211</ArticleId><ArticleId IdType="doi">10.1016/S2352-3018(20)30305-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Birol Ilter, P., Prasad, S., Berkkan, M., Mutlu, M.A., Tekin, A.B., Celik, E., Ata, B., Turgal, M., Yildiz, S., Turkgeldi, E., et al. (2022). Clinical severity of SARS-CoV-2 infection among vaccinated and unvaccinated pregnancies during the Omicron wave. Ultrasound Obstet &amp; Gyne 59, 560&#x2013;562.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/uog.24893</ArticleId></ArticleIdList></Reference><Reference><Citation>Branche, A.R., Rouphael, N.G., Diemert, D.J., Falsey, A.R., Losada, C., Baden, L.R., Frey, S.E., Whitaker, J.A., Little, S.J., Anderson, E.J., et al. (2023). Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial. Nat Med 29, 2334&#x2013;2346.</Citation><ArticleIdList><ArticleId IdType="pubmed">37640860</ArticleId><ArticleId IdType="pmc">10504073</ArticleId><ArticleId IdType="doi">10.1038/s41591-023-02503-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Brodin, P. (2022). SARS-CoV-2 infections in children: understanding diverse outcomes. Immunity 55, 201&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pubmed">35093190</ArticleId><ArticleId IdType="pmc">8769938</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2022.01.014</ArticleId></ArticleIdList></Reference><Reference><Citation>Cader, M.Z., and Kaser, A. (2013). Recent advances in inflammatory bowel disease: mucosal immune cells in intestinal inflammation. Gut 62, 1653&#x2013;1664.</Citation><ArticleIdList><ArticleId IdType="pubmed">24104886</ArticleId><ArticleId IdType="doi">10.1136/gutjnl-2012-303955</ArticleId></ArticleIdList></Reference><Reference><Citation>Caillard, S., and Thaunat, O. (2021). COVID-19 vaccination in kidney transplant recipients. Nat Rev Nephrol 17, 785&#x2013;787.</Citation><ArticleIdList><ArticleId IdType="pubmed">34580488</ArticleId><ArticleId IdType="pmc">8475856</ArticleId><ArticleId IdType="doi">10.1038/s41581-021-00491-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao, Y., Jian, F., Wang, J., Yu, Y., Song, W., Yisimayi, A., Wang, J., An, R., Chen, X., Zhang, N., et al. (2022). Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. Nature 521&#x2013;529.</Citation></Reference><Reference><Citation>Cao, Y., Wang, X., Li, S., Dong, Y., Liu, Y., Li, J., Zhao, Y., and Feng, Y. (2022). A third high dose of inactivated COVID-19 vaccine induces higher neutralizing antibodies in humans against the Delta and Omicron variants: a randomized, double-blinded clinical trial. Sci China Life Sci 65, 1677&#x2013;1679.</Citation><ArticleIdList><ArticleId IdType="pubmed">35441932</ArticleId><ArticleId IdType="pmc">9020148</ArticleId><ArticleId IdType="doi">10.1007/s11427-022-2110-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Card, T.R., Nakafero, G., Grainge, M.J., Mallen, C.D., Van-Tam, J.S.N., Williams, H.C., and Abhishek, A. (2023). Is vaccination against COVID-19 associated with inflammatory bowel disease flare? Self-controlled case series analysis using the UK CPRD. Am J Gastroenterol 118, 1388&#x2013;1394.</Citation><ArticleIdList><ArticleId IdType="pubmed">36826512</ArticleId><ArticleId IdType="doi">10.14309/ajg.0000000000002205</ArticleId></ArticleIdList></Reference><Reference><Citation>Castillo-Aleman, Y.M., Villegas-Valverde, C.A., Ventura-Carmenate, Y., Suarez-Formigo, G.M., and Bencomo-Hernandez, A.A. (2022). &#x201c;Original Antigenic Sin&#x201d; in SARS-CoV-2 vaccination followed by infection. Cureus 14, e32548.</Citation><ArticleIdList><ArticleId IdType="pubmed">36540317</ArticleId><ArticleId IdType="pmc">9756105</ArticleId></ArticleIdList></Reference><Reference><Citation>Catal&#xe0;, M., Mercad&#xe9;-Besora, N., Kolde, R., Trinh, N.T.H., Roel, E., Burn, E., Rathod-Mistry, T., Kostka, K., Man, W.Y., Delmestri, A., et al. (2024). The effectiveness of COVID-19 vaccines to prevent long COVID symptoms: staggered cohort study of data from the UK, Spain, and Estonia. Lancet Respir Med 12, 225&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pubmed">38219763</ArticleId><ArticleId IdType="doi">10.1016/S2213-2600(23)00414-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceban, F., Ling, S., Lui, L.M.W., Lee, Y., Gill, H., Teopiz, K.M., Rodrigues, N.B., Subramaniapillai, M., Di Vincenzo, J.D., Cao, B., et al. (2022). Fatigue and cognitive impairment in Post-COVID-19 Syndrome: a systematic review and meta-analysis. Brain Behav Immun 101, 93&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">34973396</ArticleId><ArticleId IdType="doi">10.1016/j.bbi.2021.12.020</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakraborty, C., Bhattacharya, M., and Dhama, K. (2023). SARS-CoV-2 vaccines, vaccine development technologies, and significant efforts in vaccine development during the pandemic: the lessons learned might help to fight against the next pandemic. Vaccines 11, 682.</Citation><ArticleIdList><ArticleId IdType="pubmed">36992266</ArticleId><ArticleId IdType="pmc">10054865</ArticleId><ArticleId IdType="doi">10.3390/vaccines11030682</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalkias, S., Whatley, J.L., Eder, F., Essink, B., Khetan, S., Bradley, P., Brosz, A., McGhee, N., Tomassini, J.E., Chen, X., et al. (2023). Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results. Nat Med 29, 2325&#x2013;2333.</Citation><ArticleIdList><ArticleId IdType="pubmed">37653342</ArticleId><ArticleId IdType="pmc">10504066</ArticleId><ArticleId IdType="doi">10.1038/s41591-023-02517-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalkias S., M.N., Whatley J. L., Essink B., Brosz A., Tomassini J. E., Girard B., Edwards D. K., Nasir A., Lee D., Avena L. E., Feng J., Deng W. P., Montefiori D. C., Baden L. R., Miller J. M., Das R. (2023). Safety and immunogenicity of XBB.1.5-containing mRNA vaccines. MedRxiv doi: https://doi.org/10.1101/2023.08.22.23293434 .</Citation></Reference><Reference><Citation>Chen, G.L., Qiu, Y.Z., Wu, K.Q., Wu, Y., Wang, Y.H., Zou, Y.Y., Peng, C.G., Zhao, J., Su, C., Ma, J.H., et al. (2023). Safety and immunogenicity of primary vaccination with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: two randomized, observer-blinded, placebo-controlled and dose-escalation phase 1 clinical trials. Hum Vaccines ImmunoTher 19, 2285089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2023.2285089</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng, C., Wang, Y., Hu, D., Zhou, W., Liu, C., Tian, X., Zhang, H., Xu, Y.C., and Xu, K.F. (2022). Humoral response to inactivated SARS-CoV-2 vaccines in patients on sirolimus alone. Sci China Life Sci 65, 2118&#x2013;2120.</Citation><ArticleIdList><ArticleId IdType="pubmed">35471686</ArticleId><ArticleId IdType="pmc">9039973</ArticleId><ArticleId IdType="doi">10.1007/s11427-022-2102-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi H. S., K.M.-H., Choi M. G., Park J.H., and Chun E.M. (2023). Hematologic abnormalities after COVID-19 vaccination: A large Korean population-based cohort study. MedRxiv doi: https://doi.org/10.1101/2023.11.15.23298565 .</Citation></Reference><Reference><Citation>Chou, J., Thomas, P.G., and Randolph, A.G. (2022). Immunology of SARS-CoV-2 infection in children. Nat Immunol 23, 177&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">35105983</ArticleId><ArticleId IdType="pmc">8981222</ArticleId><ArticleId IdType="doi">10.1038/s41590-021-01123-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Christenson, S.A., Smith, B.M., Bafadhel, M., and Putcha, N. (2022). Chronic obstructive pulmonary disease. Lancet 399, 2227&#x2013;2242.</Citation><ArticleIdList><ArticleId IdType="pubmed">35533707</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(22)00470-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Creech, C.B., Walker, S.C., and Samuels, R.J. (2021). SARS-CoV-2 vaccines. JAMA 325, 1318&#x2013;1320.</Citation><ArticleIdList><ArticleId IdType="pubmed">33635317</ArticleId><ArticleId IdType="doi">10.1001/jama.2021.3199</ArticleId></ArticleIdList></Reference><Reference><Citation>Curtis, J.R., Johnson, S.R., Anthony, D.D., Arasaratnam, R.J., Baden, L.R., Bass, A.R., Calabrese, C., Gravallese, E.M., Harpaz, R., Kroger, A., et al. (2023). American College of Rheumatology Guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 5. Arthritis Rheumatology 75, E1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">36345691</ArticleId><ArticleId IdType="doi">10.1002/art.42372</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai, L., Gao, L., Tao, L., Hadinegoro, S.R., Erkin, M., Ying, Z., He, P., Girsang, R.T., Vergara, H., Akram, J., et al. (2022). Efficacy and safety of the RBD-Dimer-based Covid-19 vaccine ZF2001 in adults. N Engl J Med 386, 2097&#x2013;2111.</Citation><ArticleIdList><ArticleId IdType="pubmed">35507481</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2202261</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai, M., Liu, D., Liu, M., Zhou, F., Li, G., Chen, Z., Zhang, Z., You, H., Wu, M., Zheng, Q., et al. (2020). Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Canc Discov 10, 783&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.CD-20-0422</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis, H.E., McCorkell, L., Vogel, J.M., and Topol, E.J. (2023). Long COVID: Major findings, mechanisms and recommendations. Nat Rev Microbiol 21, 133&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pubmed">36639608</ArticleId><ArticleId IdType="pmc">9839201</ArticleId><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Dayan, G.H., Rouphael, N., Walsh, S.R., Chen, A., Grunenberg, N., Allen, M., Antony, J., Asante, K.P., Bhate, A.S., Beresnev, T., et al. (2023). Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial. Lancet Respir Med 11, 975&#x2013;990.</Citation><ArticleIdList><ArticleId IdType="pubmed">37716365</ArticleId><ArticleId IdType="doi">10.1016/S2213-2600(23)00263-1</ArticleId></ArticleIdList></Reference><Reference><Citation>De Rose, D.U., Salvatori, G., Dotta, A., and Auriti, C. (2022). SARS-CoV-2 vaccines during pregnancy and breastfeeding: a systematic review of maternal and neonatal outcomes. Viruses 14, 539.</Citation><ArticleIdList><ArticleId IdType="pubmed">35336947</ArticleId><ArticleId IdType="pmc">8951373</ArticleId><ArticleId IdType="doi">10.3390/v14030539</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Noia, V., Pimpinelli, F., Renna, D., Barberi, V., Maccallini, M.T., Gariazzo, L., Pontone, M., Monti, A., Campo, F., Taraborelli, E., et al. (2021). Immunogenicity and safety of COVID-19 vaccine BNT162b2 for patients with solid cancer: a large cohort prospective study from a single institution. Clin Canc Res 27, 6815&#x2013;6823.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-21-2439</ArticleId></ArticleIdList></Reference><Reference><Citation>Dicembrini, I., Scoccimarro, D., Del Vescovo, G.G., Marinelli, C., Zago, E., Delli Poggi, C., Pala, L., and Mannucci, E. (2023). Patient-reported outcomes of COVID-19 vaccine breakthrough infection-associated changes in glucose control in subjects with type 1 diabetes (PRO-VACS 2 Study). Diabetes Care 46, e8&#x2013;e9.</Citation><ArticleIdList><ArticleId IdType="pubmed">36375126</ArticleId><ArticleId IdType="doi">10.2337/dc22-0868</ArticleId></ArticleIdList></Reference><Reference><Citation>Dionne, A., Sperotto, F., Chamberlain, S., Baker, A.L., Powell, A.J., Prakash, A., Castellanos, D.A., Saleeb, S.F., de Ferranti, S.D., Newburger, J.W., et al. (2021). Association ofmyocarditis with BNT162b2 messenger RNA COVID-19 vaccine in a case series of children. JAMA Cardiol 6, 1446&#x2013;1450.</Citation><ArticleIdList><ArticleId IdType="pubmed">34374740</ArticleId><ArticleId IdType="doi">10.1001/jamacardio.2021.3471</ArticleId></ArticleIdList></Reference><Reference><Citation>Efros, O., Anteby, R., Halfon, M., Meisel, E., Klang, E., and Soffer, S. (2022). Efficacy and safety of third dose of the COVID-19 vaccine among solid organ transplant recipients: a systemic review and meta-analysis. Vaccines 10, 95.</Citation><ArticleIdList><ArticleId IdType="pubmed">35062756</ArticleId><ArticleId IdType="pmc">8778934</ArticleId><ArticleId IdType="doi">10.3390/vaccines10010095</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehmsen, S., Asmussen, A., Jeppesen, S.S., Nilsson, A.C., &#xd8;sterlev, S., Vestergaard, H., Justesen, U.S., Johansen, I.S., Frederiksen, H., and Ditzel, H.J. (2021). Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer. Canc Cell 39, 1034&#x2013;1036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2021.07.016</ArticleId></ArticleIdList></Reference><Reference><Citation>Faksova, K., Walsh, D., Jiang, Y., Griffin, J., Phillips, A., Gentile, A., Kwong, J.C., Macartney, K., Naus, M., Grange, Z., et al. (2024). COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals. Vaccine 42, 2200&#x2013;2211.</Citation><ArticleIdList><ArticleId IdType="pubmed">38350768</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2024.01.100</ArticleId></ArticleIdList></Reference><Reference><Citation>Falsaperla, R., Leone, G., Familiari, M., and Ruggieri, M. (2021). COVID-19 vaccination in pregnant and lactating women: a systematic review. Expert Rev Vaccines 20, 1619&#x2013;1628.</Citation><ArticleIdList><ArticleId IdType="pubmed">34592123</ArticleId><ArticleId IdType="doi">10.1080/14760584.2021.1986390</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldstein, L.R., Tenforde, M.W., Friedman, K.G., Newhams, M., Rose, E.B., Dapul, H., Soma, V.L., Maddux, A.B., Mourani, P.M., Bowens, C., et al. (2021). Characteristics and outcomes of us children and adolescents with multisystem inflammatory syndrome in children (MIS-C) compared with severe acute COVID-19. JAMA 325, 1074&#x2013;1087.</Citation><ArticleIdList><ArticleId IdType="pubmed">33625505</ArticleId><ArticleId IdType="doi">10.1001/jama.2021.2091</ArticleId></ArticleIdList></Reference><Reference><Citation>Fendler, A., Shepherd, S.T.C., Au, L., Wu, M., Harvey, R., Schmitt, A.M., Tippu, Z., Shum, B., Farag, S., Rogiers, A., et al. (2022). Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer. Lancet 399, 905&#x2013;907.</Citation><ArticleIdList><ArticleId IdType="pubmed">35090602</ArticleId><ArticleId IdType="pmc">8789238</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(22)00147-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Flores-Vega, V.R., Monroy-Molina, J.V., Jim&#xe9;nez-Hern&#xe1;ndez, L.E., Torres, A.G., Santos-Preciado, J.I., and Rosales-Reyes, R. (2022). SARS-CoV-2: evolution and emergence of new viral variants. Viruses 14, 653.</Citation><ArticleIdList><ArticleId IdType="pubmed">35458383</ArticleId><ArticleId IdType="pmc">9025907</ArticleId><ArticleId IdType="doi">10.3390/v14040653</ArticleId></ArticleIdList></Reference><Reference><Citation>Frater, J., Ewer, K.J., Ogbe, A., Pace, M., Adele, S., Adland, E., Alagaratnam, J., Aley, P.K., Ali, M., Ansari, M.A., et al. (2021a). Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: A single-arm substudy of a phase 2/3 clinical trial. Lancet HIV 8, e474&#x2013;e485.</Citation><ArticleIdList><ArticleId IdType="pubmed">34153264</ArticleId><ArticleId IdType="pmc">8213361</ArticleId><ArticleId IdType="doi">10.1016/S2352-3018(21)00103-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Frenck Jr., R.W., Klein, N.P., Kitchin, N., Gurtman, A., Absalon, J., Lockhart, S., Perez, J.L., Walter, E.B., Senders, S., Bailey, R., et al. (2021). Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. N Engl J Med 385, 239&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">34043894</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2107456</ArticleId></ArticleIdList></Reference><Reference><Citation>Galmiche, S., Luong Nguyen, L.B., Tartour, E., de Lamballerie, X., Wittkop, L., Loubet, P., and Launay, O. (2022). Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: A systematic review. Clin Microbiol Infect 28, 163&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">35020589</ArticleId><ArticleId IdType="doi">10.1016/j.cmi.2021.09.036</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao, B., He, L., Bao, Y., Chen, Y., Lu, G., Zhang, Y., Xu, Y., Su, B., Xu, J., Wang, Y., et al. (2023). Repeated vaccination of inactivated SARS-CoV-2 vaccine dampens neutralizing antibodies against Omicron variants in breakthrough infection. Cell Res 33, 258&#x2013;261.</Citation><ArticleIdList><ArticleId IdType="pubmed">36697703</ArticleId><ArticleId IdType="pmc">9875169</ArticleId><ArticleId IdType="doi">10.1038/s41422-023-00781-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge, J., Digitale, J.C., Pletcher, M.J., and Lai, J.C. (2023). Breakthrough SARS-CoV-2 infection outcomes in vaccinated patients with chronic liver disease and cirrhosis: a national COVID cohort collaborative study. Hepatology 77, 834&#x2013;850.</Citation><ArticleIdList><ArticleId IdType="pubmed">36799617</ArticleId><ArticleId IdType="doi">10.1002/hep.32780</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerber, J.S., and Offit, P.A. (2021). COVID-19 vaccines for children. Science 374, 913.</Citation><ArticleIdList><ArticleId IdType="pubmed">34793207</ArticleId><ArticleId IdType="doi">10.1126/science.abn2566</ArticleId></ArticleIdList></Reference><Reference><Citation>Geretti, A.M., Stockdale, A.J., Kelly, S.H., Cevik, M., Collins, S., Waters, L., Villa, G., Docherty, A., Harrison, E.M., Turtle, L., et al. (2021). Outcomes of coronavirus disease 2019 (COVID-19) related hospitalization among people with human immunodeficiency virus (HIV) in the ISARIC World Health Organization (WHO) clinical characterization protocol (UK): a prospective observational study. Clin Infect Dis 73, e2095&#x2013;e2106.</Citation><ArticleIdList><ArticleId IdType="pubmed">33095853</ArticleId><ArticleId IdType="doi">10.1093/cid/ciaa1605</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldshtein, I., Steinberg, D.M., Kuint, J., Chodick, G., Segal, Y., Shapiro Ben David, S., and Ben-Tov, A. (2022). Association of BNT162b2 COVID-19 vaccination during pregnancy with neonatal and early infant outcomes. JAMA Pediatr 176, 470&#x2013;477.</Citation><ArticleIdList><ArticleId IdType="pubmed">35142809</ArticleId><ArticleId IdType="pmc">8832306</ArticleId><ArticleId IdType="doi">10.1001/jamapediatrics.2022.0001</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomes, D., Beyerlein, A., Katz, K., Hoelscher, G., Nennstiel, U., Liebl, B., &#xdc;berla, K., von Kries, R., and Adnan, M. (2021). Is the BNT162b2 COVID-19 vaccine effective in elderly populations? Results from population data from Bavaria, Germany. PLoS ONE 16, e0259370.</Citation><ArticleIdList><ArticleId IdType="pubmed">34739520</ArticleId><ArticleId IdType="pmc">8570490</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0259370</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;tzinger, F., Santiago-Garc&#xed;a, B., Noguera-Juli&#xe1;n, A., Lanaspa, M., Lancella, L., Cal&#xf2; Carducci, F.I., Gabrovska, N., Velizarova, S., Prunk, P., Osterman, V., et al. (2020). COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. Lancet Child Adolesc Health 4, 653&#x2013;661.</Citation><ArticleIdList><ArticleId IdType="pubmed">32593339</ArticleId><ArticleId IdType="pmc">7316447</ArticleId><ArticleId IdType="doi">10.1016/S2352-4642(20)30177-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham, D.B., and Xavier, R.J. (2020). Pathway paradigms revealed from the genetics of inflammatory bowel disease. Nature 578, 527&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">32103191</ArticleId><ArticleId IdType="pmc">7871366</ArticleId><ArticleId IdType="doi">10.1038/s41586-020-2025-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta, S., Su, H., Narsai, T., and Agrawal, S. (2021). SARS-CoV-2-associated T-cell responses in the presence of humoral immunodeficiency. Int Arch Allergy Immunol 182, 195&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pubmed">33486489</ArticleId><ArticleId IdType="doi">10.1159/000514193</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe4;gg, S., and Religa, D. (2022). COVID vaccination in older adults. Nat Microbiol 7, 1106&#x2013;1107.</Citation><ArticleIdList><ArticleId IdType="pubmed">35836001</ArticleId><ArticleId IdType="doi">10.1038/s41564-022-01166-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagin, D., Freund, T., Navon, M., Halperin, T., Adir, D., Marom, R., Levi, I., Benor, S., Alcalay, Y., and Freund, N.T. (2021). Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity. J Allergy Clin Immunol 148, 739&#x2013;749.</Citation><ArticleIdList><ArticleId IdType="pubmed">34087242</ArticleId><ArticleId IdType="pmc">8168345</ArticleId><ArticleId IdType="doi">10.1016/j.jaci.2021.05.029</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall, V.G., and Teh, B.W. (2023). COVID-19 vaccination in patients with cancer and patients receiving HSCT or CAR-T therapy: immune response, real-world effectiveness, and implications for the future. J Infect Dis 228, S55&#x2013;S69.</Citation><ArticleIdList><ArticleId IdType="pubmed">37539765</ArticleId><ArticleId IdType="pmc">10401617</ArticleId><ArticleId IdType="doi">10.1093/infdis/jiad174</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamad Saied, M., van der Griend, L., van Straalen, J.W., Wulffraat, N.M., Vastert, S., and Jansen, M.H.A. (2023). The protective effect of COVID-19 vaccines on developing multisystem inflammatory syndrome in children (MIS-C): a systematic literature review and meta-analysis. Pediatr Rheumatol 21, 80.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12969-023-00848-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Hannawi, S., Saf Eldin, L., Abuquta, A., Alamadi, A., Mahmoud, S.A., Hassan, A., Xu, S., Li, J., Liu, D., Baidoo, A.A.H., et al. (2023a). Safety and immunogenicity of a tetravalent and bivalent SARS-CoV-2 protein booster vaccine in men. Nat Commun 14, 4043.</Citation><ArticleIdList><ArticleId IdType="pubmed">37422518</ArticleId><ArticleId IdType="pmc">10329711</ArticleId><ArticleId IdType="doi">10.1038/s41467-023-39766-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Hannawi, S., Yan, L., Saf Eldin, L., Abuquta, A., Alamadi, A., Mahmoud, S.A., Hassan, A., Zhang, M., Gao, C., Chen, Y., et al. (2023b). Safety and immunogenicity of multivalent SARS-CoV-2 protein vaccines: a randomized phase 3 trial. eClinical-Medicine 64, 102195.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2023.102195</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen, C.H., Moustsen-Helms, I.R., Rasmussen, M., S&#xf8;borg, B., Ullum, H., and Valentiner-Branth, P. (2024). Short-term effectiveness of the XBB.1.5 updated COVID-19 vaccine against hospitalisation in Denmark: a national cohort study. Lancet Infect Dis 24, e73&#x2013;e74.</Citation><ArticleIdList><ArticleId IdType="pubmed">38190834</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(23)00746-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Hause, A.M., Shay, D.K., Klein, N.P., Abara, W.E., Baggs, J., Cortese, M.M., Fireman, B., Gee, J., Glanz, J.M., Goddard, K., et al. (2022). Safety of COVID-19 vaccination in United States children ages 5 to 11 years. Pediatrics 150, e2022057313.</Citation><ArticleIdList><ArticleId IdType="pubmed">35581698</ArticleId><ArticleId IdType="doi">10.1542/peds.2022-057313</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermens, J.M., and Kesmir, C. (2023). Role of T cells in severe COVID-19 disease, protection, and long term immunity. Immunogenetics 75, 295&#x2013;307.</Citation><ArticleIdList><ArticleId IdType="pubmed">36752852</ArticleId><ArticleId IdType="pmc">9905767</ArticleId><ArticleId IdType="doi">10.1007/s00251-023-01294-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Hippisley-Cox, J., Coupland, C.A., Mehta, N., Keogh, R.H., Diaz-Ordaz, K., Khunti, K., Lyons, R.A., Kee, F., Sheikh, A., Rahman, S., et al. (2021). Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study. BMJ 374, n2244.</Citation><ArticleIdList><ArticleId IdType="pubmed">34535466</ArticleId><ArticleId IdType="doi">10.1136/bmj.n2244</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann, C., Casado, J.L., H&#xe4;rter, G., Vizcarra, P., Moreno, A., Cattaneo, D., Meraviglia, P., Spinner, C.D., Schabaz, F., Grunwald, S., et al. (2021). Immune deficiency is a risk factor for severe COVID-19 in people living with HIV. HIV Med 22, 372&#x2013;378.</Citation><ArticleIdList><ArticleId IdType="pubmed">33368966</ArticleId><ArticleId IdType="doi">10.1111/hiv.13037</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu, Y.F., Yuen, T.T.T., Gong, H.R., Hu, B., Hu, J.C., Lin, X.S., Rong, L., Zhou, C.L., Chen, L.L., Wang, X., et al. (2023). Rational design of a booster vaccine against COVID-19 based on antigenic distance. Cell Host Microbe 31, 1301&#x2013;1316.e8.</Citation><ArticleIdList><ArticleId IdType="pubmed">37527659</ArticleId><ArticleId IdType="doi">10.1016/j.chom.2023.07.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu, Z., Yin, Y., Wang, K., Xu, M., Ding, C., Song, Y., Yi, C., Li, J., Yi, Y., and Peng, Z. (2022). Impact of inactivated COVID-19 vaccines on viral shedding in B.1.617.2 (Delta) variant-infected patients. Sci China Life Sci 65, 2556&#x2013;2559.</Citation><ArticleIdList><ArticleId IdType="pubmed">35717433</ArticleId><ArticleId IdType="pmc">9206421</ArticleId><ArticleId IdType="doi">10.1007/s11427-021-2115-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang, C.Q., Vishwanath, S., Carnell, G.W., Chan, A.C.Y., and Heeney, J.L. (2023). Immune imprinting and next-generation coronavirus vaccines. Nat Microbiol 8, 1971&#x2013;1985.</Citation><ArticleIdList><ArticleId IdType="pubmed">37932355</ArticleId><ArticleId IdType="doi">10.1038/s41564-023-01505-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang, J.K., Zhang, T., Wang, A.Z., and Li, Z. (2021). COVID-19 vaccines for patients with cancer: Benefits likely outweigh risks. J Hematol Oncol 14, 38.</Citation><ArticleIdList><ArticleId IdType="pubmed">33640005</ArticleId><ArticleId IdType="pmc">7910769</ArticleId><ArticleId IdType="doi">10.1186/s13045-021-01046-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyams, C., Marlow, R., Maseko, Z., King, J., Ward, L., Fox, K., Heath, R., Tuner, A., Friedrich, Z., Morrison, L., et al. (2021). Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study. Lancet Infect Dis 21, 1539&#x2013;1548.</Citation><ArticleIdList><ArticleId IdType="pubmed">34174190</ArticleId><ArticleId IdType="pmc">8221734</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(21)00330-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Jamalidoust, M., Eilami, O., Ashkan, Z., Ziyaeyan, M., Aliabadi, N., and Habibi, M. (2023). The rates and symptoms of natural and breakthrough infection pre- and post- Covid-19 non-mRNA vaccination at various peaks amongst Iranian healthcare workers. Virol J 20, 182.</Citation><ArticleIdList><ArticleId IdType="pubmed">37596593</ArticleId><ArticleId IdType="pmc">10436397</ArticleId><ArticleId IdType="doi">10.1186/s12985-023-02156-2</ArticleId></ArticleIdList></Reference><Reference><Citation>James, D., Jena, A., Bharath, P.N., Choudhury, A., Singh, A.K., Sebastian, S., and Sharma, V. (2022). Safety of SARS-CoV-2 vaccination in patients with inflammatory bowel disease: a systematic review and meta-analysis. Digestive Liver Dis 54, 713&#x2013;721.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dld.2022.03.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Jara, A., Undurraga, E.A., Gonz&#xe1;lez, C., Paredes, F., Fontecilla, T., Jara, G., Pizarro, A., Acevedo, J., Leo, K., Leon, F., et al. (2021). Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. N Engl J Med 385, 875&#x2013;884.</Citation><ArticleIdList><ArticleId IdType="pubmed">34233097</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2107715</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang, N., Gu, P., Sun, X., Han, H., Liu, W., Song, N., and Jiang, X. (2022). Acceptance of COVID-19 vaccines in patients with chronic diseases: A cross-sectional study. J Clin Nurs 31, 3286&#x2013;3300.</Citation><ArticleIdList><ArticleId IdType="pubmed">35285111</ArticleId><ArticleId IdType="doi">10.1111/jocn.16284</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin, H., Reed, J.C., Liu, S.T.H., Ho, H., Lopes, J.P., Ramsey, N.B., Waqar, O., Rahman, F., Aberg, J.A., Bouvier, N.M., et al. (2020). Three patients with X-linked agammaglobulinemia hospitalized for COVID-19 improved with convalescent plasma. J Allergy Clin Immunol-Pract 8, 3594&#x2013;3596.e3.</Citation><ArticleIdList><ArticleId IdType="pubmed">32947026</ArticleId><ArticleId IdType="pmc">7490621</ArticleId><ArticleId IdType="doi">10.1016/j.jaip.2020.08.059</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin, L., Li, Z., Zhang, X., Li, J., and Zhu, F. (2022). CoronaVac: a review of efficacy, safety, and immunogenicity of the inactivated vaccine against SARS-CoV-2. Hum Vaccines ImmunoTher 18, 2096970.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2022.2096970</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung, Y., Wee, J.H., Kim, J.H., and Choi, H.G. (2021). The effects of previous Asthma and COPD on the susceptibility to and severity of COVID-19: a nationwide cohort study in South Korea. J Clin Med 10, 4626.</Citation><ArticleIdList><ArticleId IdType="pubmed">34682749</ArticleId><ArticleId IdType="pmc">8541474</ArticleId><ArticleId IdType="doi">10.3390/jcm10204626</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaabi, N.A., Yang, Y.K., Liang, Y., Xu, K., Zhang, X.F., Kang, Y., Jin, Y.Q., Hou, J.W., Zhang, J., Yang, T., et al. (2023). Safety and immunogenicity of a mosaic vaccine booster against Omicron and other SARS-CoV-2 variants: A randomized phase 2 trial. Sig Transduct Target Ther 8, 20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-01295-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaaijk, P., Nicolaie, M.A., van Rooijen, D., van Houten, M.A., van der Klis, F.R., Buisman, A.M., and van Binnendijk, R.S. (2020). Dynamics of the antibody response after a third dose of measles-mumps-rubella vaccine indicate a slower decline compared with a second dose. Open Forum Infect Dis 7, ofaa505.</Citation><ArticleIdList><ArticleId IdType="pubmed">33269296</ArticleId><ArticleId IdType="pmc">7686655</ArticleId><ArticleId IdType="doi">10.1093/ofid/ofaa505</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamar, N., Abravanel, F., Marion, O., Couat, C., Izopet, J., and Del Bello, A. (2021). Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients. N Engl J Med 385, 661&#x2013;662.</Citation><ArticleIdList><ArticleId IdType="pubmed">34161700</ArticleId><ArticleId IdType="doi">10.1056/NEJMc2108861</ArticleId></ArticleIdList></Reference><Reference><Citation>Karaba, A.H., Johnston, T.S., Aytenfisu, T.Y., Akinde, O., Eby, Y., Ruff, J.E., Abedon, A.T., Alejo, J.L., Blankson, J.N., Cox, A.L., et al. (2022). A fourth dose of COVID-19 vaccine does not induce neutralization of the Omicron variant among solid organ transplant recipients with suboptimal vaccine response. Transplantation 106, 1440&#x2013;1444.</Citation><ArticleIdList><ArticleId IdType="pubmed">35417115</ArticleId><ArticleId IdType="pmc">9213052</ArticleId><ArticleId IdType="doi">10.1097/TP.0000000000004140</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy, N.A., Lin, S., Goodhand, J.R., Chanchlani, N., Hamilton, B., Bewshea, C., Nice, R., Chee, D., Cummings, J.F., Fraser, A., et al. (2021). Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Gut 70, 1884&#x2013;1893.</Citation><ArticleIdList><ArticleId IdType="pubmed">33903149</ArticleId><ArticleId IdType="doi">10.1136/gutjnl-2021-324789</ArticleId></ArticleIdList></Reference><Reference><Citation>Kharbanda, E.O., Haapala, J., DeSilva, M., Vazquez-Benitez, G., Vesco, K.K., Naleway, A.L., and Lipkind, H.S. (2021). Spontaneous abortion following COVID-19 vaccination during pregnancy. JAMA 326, 1629&#x2013;1631.</Citation><ArticleIdList><ArticleId IdType="pubmed">34495304</ArticleId><ArticleId IdType="pmc">8427483</ArticleId><ArticleId IdType="doi">10.1001/jama.2021.15494</ArticleId></ArticleIdList></Reference><Reference><Citation>Koutsakos, M., and Ellebedy, A.H. (2023). Immunological imprinting: Understanding COVID-19. Immunity 56, 909&#x2013;913.</Citation><ArticleIdList><ArticleId IdType="pubmed">37105169</ArticleId><ArticleId IdType="pmc">10113596</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2023.04.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreps, S., Prasad, S., Brownstein, J.S., Hswen, Y., Garibaldi, B.T., Zhang, B., and Kriner, D.L. (2020). Factors associated with US adults&#x2019; likelihood of accepting COVID-19 vaccination. JAMA Netw Open 3, e2025594.</Citation><ArticleIdList><ArticleId IdType="pubmed">33079199</ArticleId><ArticleId IdType="pmc">7576409</ArticleId><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.25594</ArticleId></ArticleIdList></Reference><Reference><Citation>Frerichs, K.A., Bosman, P.W.C., van Velzen, J.F., Fraaij, P.L.A., Koopmans, M.P.G., Rimmelzwaan, G.F., Nijhof, I.S., Bloem, A.C., Mutis, T., Zweegman, S., et al. (2020). Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients. Haematologica 105, e302&#x2013;e306.</Citation><ArticleIdList><ArticleId IdType="pubmed">31558675</ArticleId><ArticleId IdType="pmc">7271608</ArticleId><ArticleId IdType="doi">10.3324/haematol.2019.231860</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacedonia, D., Scioscia, G., Santomasi, C., Fuso, P., Carpagnano, G.E., Portacci, A., Mastroianni, F., Larizza, G., Sabato, E., Profilo, E., et al. (2021). Impact of smoking, COPD and comorbidities on the mortality of COVID-19 patients. Sci Rep 11, 19251.</Citation><ArticleIdList><ArticleId IdType="pubmed">34584165</ArticleId><ArticleId IdType="pmc">8478875</ArticleId><ArticleId IdType="doi">10.1038/s41598-021-98749-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau, J.J., Cheng, S.M.S., Leung, K., Lee, C.K., Hachim, A., Tsang, L.C.H., Yam, K.W.H., Chaothai, S., Kwan, K.K.H., Chai, Z.Y.H., et al. (2023). Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population. Nat Med 29, 348&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">36652990</ArticleId><ArticleId IdType="pmc">9941049</ArticleId><ArticleId IdType="doi">10.1038/s41591-023-02219-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, A.R.Y.B., Wong, S.Y., Chai, L.Y.A., Lee, S.C., Lee, M.X., Muthiah, M.D., Tay, S.H., Teo, C.B., Tan, B.K.J., Chan, Y.H., et al. (2022a). Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ 376, e068632.</Citation><ArticleIdList><ArticleId IdType="pubmed">35236664</ArticleId><ArticleId IdType="doi">10.1136/bmj-2021-068632</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, Y.J., Kim, S.E., Park, Y.E., Chang, J.Y., Song, H.J., Kim, D.H., Yang, Y.J., Kim, B.C., Lee, J.G., Yang, H.C., et al. (2022b). SARS-CoV-2 vaccination for adult patients with inflammatory bowel disease: expert consensus statement by KASID. Intest Res 20, 171&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pubmed">34974674</ArticleId><ArticleId IdType="pmc">9081989</ArticleId><ArticleId IdType="doi">10.5217/ir.2021.00098</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy, I., Wieder-Finesod, A., Litchevsky, V., Biber, A., Indenbaum, V., Olmer, L., Huppert, A., Mor, O., Goldstein, M., Levin, E.G., et al. (2021). Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1. Clin Microbiol Infect 27, 1851&#x2013;1855.</Citation><ArticleIdList><ArticleId IdType="pubmed">34438069</ArticleId><ArticleId IdType="pmc">8382485</ArticleId><ArticleId IdType="doi">10.1016/j.cmi.2021.07.031</ArticleId></ArticleIdList></Reference><Reference><Citation>Liew, F., Talwar, S., Cross, A., Willett, B.J., Scott, S., Logan, N., Siggins, M.K., Swieboda, D., Sidhu, J.K., Efstathiou, C., et al. (2023). SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination. eBioMedicine 87, 104402.</Citation><ArticleIdList><ArticleId IdType="pubmed">36543718</ArticleId><ArticleId IdType="doi">10.1016/j.ebiom.2022.104402</ArticleId></ArticleIdList></Reference><Reference><Citation>Ligumsky, H., Safadi, E., Etan, T., Vaknin, N., Waller, M., Croll, A., Nikolaevski-Berlin, A., Greenberg, I., Halperin, T., Wasserman, A., et al. (2022). Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine among actively treated cancer patients. JNCI-J Natl Canc Institute 114, 203&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnci/djab174</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin, W.H.W., Moran, E., Adams, R.J., Sievers, R.E., Hauer, D., Godin, S., and Griffin, D. E. (2020). A durable protective immune response to wild-type measles virus infection of macaques is due to viral replication and spread in lymphoid tissues. Sci Transl Med 12, eaax7799.</Citation><ArticleIdList><ArticleId IdType="pubmed">32238577</ArticleId><ArticleId IdType="pmc">7895323</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aax7799</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin, Y.C., Lai, T.S., Lin, S.L., Chen, Y.M., Chu, T.S., and Tu, Y.K. (2021). Outcomes of coronavirus 2019 infection in patients with chronic kidney disease: a systematic review and meta-analysis. Ther Adv Chronic Dis 12, 2040622321998860.</Citation><ArticleIdList><ArticleId IdType="pubmed">33796245</ArticleId><ArticleId IdType="pmc">7985947</ArticleId><ArticleId IdType="doi">10.1177/2040622321998860</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipkind, H.S., Vazquez-Benitez, G., DeSilva, M., Vesco, K.K., Ackerman-Banks, C., Zhu, J., Boyce, T.G., Daley, M.F., Fuller, C.C., Getahun, D., et al. (2022). Receipt of COVID-19 vaccine during pregnancy and preterm or small-for-gestational-age at birth &#x2014; Eight Integrated Health Care Organizations, United States, December 15, 2020-July 22, 2021. MMWR Morb Mortal Wkly Rep 71, 26&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">34990445</ArticleId><ArticleId IdType="pmc">8735559</ArticleId><ArticleId IdType="doi">10.15585/mmwr.mm7101e1</ArticleId></ArticleIdList></Reference><Reference><Citation>Lippi, G., Wong, J., and Henry, B.M. (2020). Hypertension in patients with coronavirus disease 2019 (COVID-19): a pooled analysis. Pol Arch Intern Med 130, 304&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">32231171</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez Bernal, J., Andrews, N., Gower, C., Robertson, C., Stowe, J., Tessier, E., Simmons, R., Cottrell, S., Roberts, R., O&#x2019;Doherty, M., et al. (2021). Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ 373, n1088.</Citation><ArticleIdList><ArticleId IdType="pubmed">33985964</ArticleId><ArticleId IdType="doi">10.1136/bmj.n1088</ArticleId></ArticleIdList></Reference><Reference><Citation>Luxenburger, H., and Thimme, R. (2023). SARS-CoV-2 and the liver: clinical and immunological features in chronic liver disease. Gut 72, 1783&#x2013;1794.</Citation><ArticleIdList><ArticleId IdType="pubmed">37316169</ArticleId><ArticleId IdType="doi">10.1136/gutjnl-2023-329623</ArticleId></ArticleIdList></Reference><Reference><Citation>Machado, P.M., Lawson-Tovey, S., Strangfeld, A., Mateus, E.F., Hyrich, K.L., Gossec, L., Carmona, L., Rodrigues, A., Raffeiner, B., Duarte, C., et al. (2022). Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR coronavirus vaccine (COVAX) physician-reported registry. Ann Rheum Dis 81, 695&#x2013;709.</Citation><ArticleIdList><ArticleId IdType="pubmed">34972811</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2021-221490</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnus, M.C., Oakley, L., Gjessing, H.K., Stephansson, O., Engjom, H.M., Macsali, F., Juliusson, P.B., Nybo Andersen, A., and H&#xe1;berg, S.E. (2022a). Pregnancy and risk of COVID-19: a Norwegian registry-linkage study. BJOG 129, 101&#x2013;109.</Citation><ArticleIdList><ArticleId IdType="pubmed">34657368</ArticleId><ArticleId IdType="doi">10.1111/1471-0528.16969</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnus, M.C., &#xd6;rtqvist, A.K., Dahlqwist, E., Ljung, R., Sk&#xe1;r, F., Oakley, L., Macsali, F., Pasternak, B., Gjessing, H.K., H&#xe1;berg, S.E., et al. (2022b). Association of SARS-CoV-2 vaccination during pregnancy with pregnancy outcomes. JAMA 327, 1469&#x2013;1477.</Citation><ArticleIdList><ArticleId IdType="pubmed">35323851</ArticleId><ArticleId IdType="pmc">8949721</ArticleId><ArticleId IdType="doi">10.1001/jama.2022.3271</ArticleId></ArticleIdList></Reference><Reference><Citation>Marfella, R., Sardu, C., D&#x2019;Onofrio, N., Prattichizzo, F., Scisciola, L., Messina, V., La Grotta, R., Balestrieri, M.L., Maggi, P., Napoli, C., et al. (2022). Glycaemic control is associated with SARS-CoV-2 breakthrough infections in vaccinated patients with type 2 diabetes. Nat Commun 13, 2318.</Citation><ArticleIdList><ArticleId IdType="pubmed">35484164</ArticleId><ArticleId IdType="pmc">9051134</ArticleId><ArticleId IdType="doi">10.1038/s41467-022-30068-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Marking, U., Bladh, O., Aguilera, K., Yang, Y., Greilert Norin, N., Blom, K., Hober, S., Klingstr&#xf6;m, J., Havervall, S., &#xc5;berg, M., et al. (2024). Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden. Lancet Infect Dis 24, e80&#x2013;e81.</Citation><ArticleIdList><ArticleId IdType="pubmed">38190833</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(23)00779-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Marta Malesza, M.B. (2021). Factors influencing COVID-19 vaccination uptake in an elderly sample in Poland. MedRxiv.</Citation></Reference><Reference><Citation>Mazagatos, C., Monge, S., Olmedo, C., Vega, L., Gallego, P., Martin-Merino, E., Sierra, M.J., Limia, A., and Larrauri, A. (2021). Effectiveness of mRNA COVID-19 vaccines in preventing SARS-CoV-2 infections and COVID-19 hospitalisations and deaths in elderly long-term care facility residents, Spain, weeks 53 2020 to 13 2021. Eurosurveillance 26, 2100452.</Citation><ArticleIdList><ArticleId IdType="pubmed">34142647</ArticleId><ArticleId IdType="pmc">8212595</ArticleId><ArticleId IdType="doi">10.2807/1560-7917.ES.2021.26.24.2100452</ArticleId></ArticleIdList></Reference><Reference><Citation>McCusker, C., and Warrington, R. (2011). Primary immunodeficiency. All Asth Clin Immun 7, S11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1710-1492-7-S1-S11</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng, Y., Lu, W., Guo, E., Liu, J., Yang, B., Wu, P., Lin, S., Peng, T., Fu, Y., Li, F., et al. (2020). Cancer history is an independent risk factor for mortality in hospitalized COVID-19 patients: A propensity score-matched analysis. J Hematol Oncol 13, 75.</Citation><ArticleIdList><ArticleId IdType="pubmed">32522278</ArticleId><ArticleId IdType="pmc">7286218</ArticleId><ArticleId IdType="doi">10.1186/s13045-020-00907-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Menni, C., Klaser, K., May, A., Polidori, L., Capdevila, J., Louca, P., Sudre, C.H., Nguyen, L.H., Drew, D.A., Merino, J., et al. (2021). Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID symptom study app in the UK: a prospective observational study. Lancet Infect Dis 21, 939&#x2013;949.</Citation><ArticleIdList><ArticleId IdType="pubmed">33930320</ArticleId><ArticleId IdType="pmc">8078878</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(21)00224-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Meshram, H.S., Kute, V., Rane, H., Dave, R., Banerjee, S., Mishra, V., and Chauhan, S. (2022). Humoral and cellular response of COVID-19 vaccine among solid organ transplant recipients: a systematic review and meta-analysis. Transplant Infect Dis 24, e13926.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/tid.13926</ArticleId></ArticleIdList></Reference><Reference><Citation>Moline, H.L., Whitaker, M., Deng, L., Rhodes, J.C., Milucky, J., Pham, H., Patel, K., Anglin, O., Reingold, A., Chai, S.J., et al. (2021). Effectiveness of COVID-19 vaccines in preventing hospitalization among adults aged &#x2a7e; 65 years &#x2014; COVID-NET, 13 states, February&#x2013;April 2021. MMWR Morb Mortal Wkly Rep 70, 1088&#x2013;1093.</Citation><ArticleIdList><ArticleId IdType="pubmed">34383730</ArticleId><ArticleId IdType="pmc">8360274</ArticleId><ArticleId IdType="doi">10.15585/mmwr.mm7032e3</ArticleId></ArticleIdList></Reference><Reference><Citation>Monin, L., Laing, A.G., Munoz-Ruiz, M., McKenzie, D.R., del Molino del Barrio, I., Alaguthurai, T., Domingo-Vila, C., Hayday, T.S., Graham, C., Seow, J., et al. (2021). Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: Interim analysis of a prospective observational study. Lancet Oncol 22, 765&#x2013;778.</Citation><ArticleIdList><ArticleId IdType="pubmed">33930323</ArticleId><ArticleId IdType="pmc">8078907</ArticleId><ArticleId IdType="doi">10.1016/S1470-2045(21)00213-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan, H.J., Clothier, H.J., Sepulveda Kattan, G., Boyd, J.H., and Buttery, J.P. (2024). Acute disseminated encephalomyelitis and transverse myelitis following COVID-19 vaccination - A self-controlled case series analysis. Vaccine 42, 2212&#x2013;2219.</Citation><ArticleIdList><ArticleId IdType="pubmed">38350771</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2024.01.099</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukherjee, R., and Satardekar, R. (2021). Why are some coronavirus variants more infectious? J Biosci 46, 101.</Citation><ArticleIdList><ArticleId IdType="pubmed">34785628</ArticleId><ArticleId IdType="pmc">8594289</ArticleId><ArticleId IdType="doi">10.1007/s12038-021-00221-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Mumoli, N., Conte, G., Evangelista, I., Cei, M., Mazzone, A., and Colombo, A. (2021). Post-COVID or long-COVID: Two different conditions or the same? J Infect Public Health 14, 1349&#x2013;1350.</Citation><ArticleIdList><ArticleId IdType="pubmed">34426096</ArticleId><ArticleId IdType="pmc">8372476</ArticleId><ArticleId IdType="doi">10.1016/j.jiph.2021.08.019</ArticleId></ArticleIdList></Reference><Reference><Citation>Munoz, F.M., Sher, L.D., Sabharwal, C., Gurtman, A., Xu, X., Kitchin, N., Lockhart, S., Riesenberg, R., Sexter, J.M., Czajka, H., et al. (2023). Evaluation of BNT162b2 Covid-19 vaccine in children youngerthan 5 years of age. N Engl J Med 388, 621&#x2013;634.</Citation><ArticleIdList><ArticleId IdType="pubmed">36791162</ArticleId><ArticleId IdType="pmc">9947923</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2211031</ArticleId></ArticleIdList></Reference><Reference><Citation>Naylor, K.L., Kim, S.J., Smith, G., McArthur, E., Kwong, J.C., Dixon, S.N., Treleaven, D., and Knoll, G.A. (2022). Effectiveness of first, second, and third COVID-19 vaccine doses in solid organ transplant recipients: a population-based cohort study from Canada. Am J Transplant 22, 2228&#x2013;2236.</Citation><ArticleIdList><ArticleId IdType="pubmed">35578576</ArticleId><ArticleId IdType="pmc">9347443</ArticleId><ArticleId IdType="doi">10.1111/ajt.17095</ArticleId></ArticleIdList></Reference><Reference><Citation>Notarte, K.I., Catahay, J.A., Velasco, J.V., Pastrana, A., Ver, A.T., Pangilinan, F.C., Peligro, P.J., Casimiro, M., Guerrero, J.J., Gellaco, M.M.L., et al. (2022). Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: a systematic review. eClinicalMedicine 53, 101624.</Citation><ArticleIdList><ArticleId IdType="pubmed">36051247</ArticleId><ArticleId IdType="pmc">9417563</ArticleId><ArticleId IdType="doi">10.1016/j.eclinm.2022.101624</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunes, B., Rodrigues, A.P., Kislaya, I., Cruz, C., Peralta-Santos, A., Lima, J., Pinto Leite, P., Sequeira, D., Matias Dias, C., and Machado, A. (2021). mRNA vaccine effectiveness against COVID-19-related hospitalisations and deaths in older adults: A cohort study based on data linkage of national health registries in Portugal, February to August 2021. Eurosurveillance 26, 2100833.</Citation><ArticleIdList><ArticleId IdType="pubmed">34558406</ArticleId><ArticleId IdType="pmc">8462036</ArticleId><ArticleId IdType="doi">10.2807/1560-7917.ES.2021.26.38.2100833</ArticleId></ArticleIdList></Reference><Reference><Citation>N&#xfa;&#xf1;ez-Gil, I.J., Feltes, G., Viana-Llamas, M.C., Raposeiras-Roubin, S., Romero, R., Alfonso-Rodr&#xed;guez, E., Uribarri, A., Santoro, F., Becerra-Munoz, V., Pepe, M., et al. (2023). Post-COVID-19 symptoms and heart disease: incidence, prognostic factors, outcomes and vaccination: results from a multi-center international prospective registry (HOPE 2). J Clin Med 12, 706.</Citation><ArticleIdList><ArticleId IdType="pubmed">36675633</ArticleId><ArticleId IdType="pmc">9863454</ArticleId><ArticleId IdType="doi">10.3390/jcm12020706</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostchega, Y., Fryar, C.D., Nwankwo, T., and Nguyen, D.T. (2020). Hypertension prevalence among adults aged 18 and over: United States, 2017&#x2013;2018. NCHS Data Brief, 364, 1&#x2013;8.</Citation></Reference><Reference><Citation>Ozaka, S., Kobayashi, T., Mizukami, K., and Murakami, K. (2022). COVID-19 vaccination and liver disease. World J Gastroenterol 28, 6791&#x2013;6810.</Citation><ArticleIdList><ArticleId IdType="pubmed">36632314</ArticleId><ArticleId IdType="pmc">9827578</ArticleId><ArticleId IdType="doi">10.3748/wjg.v28.i48.6791</ArticleId></ArticleIdList></Reference><Reference><Citation>Paknahad, M.H., Yancheshmeh, F.B., and Soleimani, A. (2023). Cardiovascular complications of COVID-19 vaccines: a review of case-report and case-series studies. Heart Lung 59, 173&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pubmed">36842342</ArticleId><ArticleId IdType="pmc">9905103</ArticleId><ArticleId IdType="doi">10.1016/j.hrtlng.2023.02.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Park, J.H., and Lee, H.K. (2021). Delivery routes for COVID-19 vaccines. Vaccines 9, 524.</Citation><ArticleIdList><ArticleId IdType="pubmed">34069359</ArticleId><ArticleId IdType="pmc">8158705</ArticleId><ArticleId IdType="doi">10.3390/vaccines9050524</ArticleId></ArticleIdList></Reference><Reference><Citation>Patone, M., Mei, X.W., Handunnetthi, L., Dixon, S., Zaccardi, F., Shankar-Hari, M., Watkinson, P., Khunti, K., Harnden, A., Coupland, C.A.C., et al. (2022). Risk of myocarditis after sequential doses of COVID-19 vaccine and SARS-CoV-2 infection by age and sex. Circulation 146, 743&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pubmed">35993236</ArticleId><ArticleId IdType="pmc">9439633</ArticleId><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.122.059970</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xe9;rez-Galarza, J., Pr&#xf3;cel, C., Ca&#xf1;adas, C., Aguirre, D., Pibaque, R., Bed&#xf3;n, R., Semp&#xe9;rtegui, F., Drexhage, H., and Balde&#xf3;n, L. (2021). Immune response to SARS-CoV-2 infection in obesity and T2D: literature review. Vaccines 9, 102.</Citation><ArticleIdList><ArticleId IdType="pubmed">33572702</ArticleId><ArticleId IdType="pmc">7911386</ArticleId><ArticleId IdType="doi">10.3390/vaccines9020102</ArticleId></ArticleIdList></Reference><Reference><Citation>Pham, M.N., Murugesan, K., Banaei, N., Pinsky, B.A., Tang, M., Hoyte, E., Lewis, D.B., and Gernez, Y. (2022). Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects. J Allergy Clin Immunol 149, 907&#x2013;911.e3.</Citation><ArticleIdList><ArticleId IdType="pubmed">34952033</ArticleId><ArticleId IdType="doi">10.1016/j.jaci.2021.11.022</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilgram, L., Eberwein, L., Jensen, B.E.O., Jakob, C.E.M., Koehler, F.C., Hower, M., Kielstein, J.T., Stecher, M., Hohenstein, B., Prasser, F., et al. (2023). SARS-CoV-2 infection in chronic kidney disease patients with pre-existing dialysis: description across different pandemic intervals and effect on disease course (mortality). Infection 51, 71&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">35486356</ArticleId><ArticleId IdType="doi">10.1007/s15010-022-01826-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Pimenta, D., Yates, C., Pagel, C., and Gurdasani, D. (2021). Delaying the second dose of covid-19 vaccines. BMJ 372, n710.</Citation><ArticleIdList><ArticleId IdType="pubmed">33737404</ArticleId><ArticleId IdType="doi">10.1136/bmj.n710</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack, F.P., Thomas, S.J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., P&#xe9;rez Marc, G., Moreira, E.D., Zerbini, C., et al. (2020). Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 383, 2603&#x2013;2615.</Citation><ArticleIdList><ArticleId IdType="pubmed">33301246</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad, S., Kalafat, E., Blakeway, H., Townsend, R., O&#x2019;Brien, P., Morris, E., Draycott, T., Thangaratinam, S., Le Doare, K., Ladhani, S., et al. (2022). Systematic review and meta-analysis of the effectiveness and perinatal outcomes of COVID-19 vaccination in pregnancy. Nat Commun 13, 2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">35538060</ArticleId><ArticleId IdType="pmc">9090726</ArticleId><ArticleId IdType="doi">10.1038/s41467-022-30052-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Prentice, R.E., Rentsch, C., Al-Ani, A.H., Zhang, E., Johnson, D., Halliday, J., Bryant, R., Begun, J., Ward, M.G., Lewindon, P.J., et al. (2021). SARS-CoV-2 vaccination in patients with inflammatory bowel disease. GastroHep 3, 212&#x2013;228.</Citation><ArticleIdList><ArticleId IdType="pubmed">34539248</ArticleId><ArticleId IdType="pmc">8441891</ArticleId><ArticleId IdType="doi">10.1002/ygh2.473</ArticleId></ArticleIdList></Reference><Reference><Citation>Puhach, O., Adea, K., Hulo, N., Sattonnet, P., Genecand, C., Iten, A., Jacqu&#xe9;rioz, F., Kaiser, L., Vetter, P., Eckerle, I., et al. (2022). Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2. Nat Med 28, 1491&#x2013;1500.</Citation><ArticleIdList><ArticleId IdType="pubmed">35395151</ArticleId><ArticleId IdType="doi">10.1038/s41591-022-01816-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin, S., Li, Y., Wang, L., Zhao, X., Ma, X., and Gao, G.F. (2023). Assessment of vaccinations and breakthrough infections after adjustment of the dynamic zero-COVID-19 strategy in China: an online survey. Emerging Microbes Infects 12, 2258232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2023.2258232</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu, L., Yi, Z., Shen, Y., Lin, L., Chen, F., Xu, Y., Wu, Z., Tang, H., Zhang, X., Tian, F., et al. (2022). Circular RNA vaccines against SARS-CoV-2 and emerging variants. Cell 185, 1728&#x2013;1744.e16.</Citation><ArticleIdList><ArticleId IdType="pubmed">35460644</ArticleId><ArticleId IdType="pmc">8971115</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2022.03.044</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinti, I., Lougaris, V., Milito, C., Cinetto, F., Pecoraro, A., Mezzaroma, I., Mastroianni, C.M., Turriziani, O., Bondioni, M.P., Filippini, M., et al. (2020). A possible role for B cells in COVID-19? Lesson from patients with agammaglobu-linemia. J Allergy Clin Immunol 146, 211&#x2013;213.e4.</Citation><ArticleIdList><ArticleId IdType="pubmed">32333914</ArticleId><ArticleId IdType="pmc">7175894</ArticleId><ArticleId IdType="doi">10.1016/j.jaci.2020.04.013</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranzani, O.T., Hitchings, M.D.T., de Melo, R.L., de Franca, G.V.A., Fernandes, C.F.R., Lind, M.L., Torres, M.S.S., Tsuha, D.H., David, L.C.S., Said, R.F.C., et al. (2022). Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil. Nat Commun 13, 5536.</Citation><ArticleIdList><ArticleId IdType="pubmed">36202800</ArticleId><ArticleId IdType="pmc">9537178</ArticleId><ArticleId IdType="doi">10.1038/s41467-022-33169-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranzani, O.T., Hitchings, M.D.T., Dorion, M., D&#x2019;Agostini, T.L., de Paula, R.C., de Paula, O.F.P., Villela, E.F.M., Torres, M.S.S., de Oliveira, S.B., Schulz, W., et al. (2021). Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: Test negative case-control study. BMJ 374, n2015.</Citation><ArticleIdList><ArticleId IdType="pubmed">34417194</ArticleId><ArticleId IdType="doi">10.1136/bmj.n2015</ArticleId></ArticleIdList></Reference><Reference><Citation>Rieger, C.T., Liss, B., Mellinghoff, S., Buchheidt, D., Cornely, O.A., Egerer, G., Heinz, W.J., Hentrich, M., Maschmeyer, G., Mayer, K., et al. (2018). Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors&#x2014;Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). Ann Oncol 29, 1354&#x2013;1365.</Citation><ArticleIdList><ArticleId IdType="pubmed">29688266</ArticleId><ArticleId IdType="pmc">6005139</ArticleId><ArticleId IdType="doi">10.1093/annonc/mdy117</ArticleId></ArticleIdList></Reference><Reference><Citation>Rouphael, N., and Bausch-Jurken, M. (2023). COVID-19 vaccination among patients receiving maintenance renal replacement therapy: immune response, real-world effectiveness, and implications for the future. J Infect Dis 228, S46&#x2013;S54.</Citation><ArticleIdList><ArticleId IdType="pubmed">37539761</ArticleId><ArticleId IdType="pmc">10401621</ArticleId><ArticleId IdType="doi">10.1093/infdis/jiad162</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin, D.T., Abreu, M.T., Rai, V., Siegel, C.A., Ahuja, V., Allez, M., Ananthakrishnan, A.N., Bernstein, C.N., Braun, J.G., Chowers, Y., et al. (2020). Management of patients with crohn&#x2019;s disease and ulcerative colitis during the coronavirus disease-2019 pandemic: results of an international meeting. Gastroenterology 159, 6&#x2013;13.e6.</Citation><ArticleIdList><ArticleId IdType="pubmed">32272113</ArticleId><ArticleId IdType="doi">10.1053/j.gastro.2020.04.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin, L.G., Levin, M.J., Ljungman, P., Davies, E.G., Avery, R., Tomblyn, M., Bousvaros, A., Dhanireddy, S., Sung, L., Keyserling, H., et al. (2014). 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 58, e44&#x2013;e100.</Citation><ArticleIdList><ArticleId IdType="pubmed">24311479</ArticleId><ArticleId IdType="doi">10.1093/cid/cit684</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadoff, J., Gray, G., Vandebosch, A., Cardenas, V., Shukarev, G., Grinsztejn, B., Goepfert, P.A., Truyers, C., Fennema, H., Spiessens, B., et al. (2021). Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med 384, 2187&#x2013;2201.</Citation><ArticleIdList><ArticleId IdType="pubmed">33882225</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2101544</ArticleId></ArticleIdList></Reference><Reference><Citation>Saeed, S., Tadic, M., Larsen, T.H., Grassi, G., and Mancia, G. (2021). Coronavirus disease 2019 and cardiovascular complications: focused clinical review. J Hypertens 39, 1282&#x2013;1292.</Citation><ArticleIdList><ArticleId IdType="pubmed">33687179</ArticleId><ArticleId IdType="pmc">9904438</ArticleId><ArticleId IdType="doi">10.1097/HJH.0000000000002819</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakuraba, A., Luna, A., and Micic, D. (2022). A systematic review and meta-analysis of serologic response following coronavirus disease 2019 (COVID-19) vaccination in solid organ transplant recipients. Viruses 14, 1822.</Citation><ArticleIdList><ArticleId IdType="pubmed">36016444</ArticleId><ArticleId IdType="pmc">9413038</ArticleId><ArticleId IdType="doi">10.3390/v14081822</ArticleId></ArticleIdList></Reference><Reference><Citation>Schinas, G., Polyzou, E., Mitropetrou, F., Pazionis, A., Gogos, C., Triantos, C., and Akinosoglou, K. (2022). COVID-19 vaccination in patients with chronic liver disease. Viruses 14, 2778.</Citation><ArticleIdList><ArticleId IdType="pubmed">36560782</ArticleId><ArticleId IdType="pmc">9785164</ArticleId><ArticleId IdType="doi">10.3390/v14122778</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt, T., Klemis, V., Schub, D., Schneitler, S., Reichert, M.C., Wilkens, H., Sester, U., Sester, M., and Mihm, J. (2021). Cellular immunity predominates over humoral immunity after homologous and heterologous mRNA and vector-based COVID-19 vaccine regimens in solid organ transplant recipients. Am J Transplant 21, 3990&#x2013;4002.</Citation><ArticleIdList><ArticleId IdType="pubmed">34453872</ArticleId><ArticleId IdType="doi">10.1111/ajt.16818</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider, J.L., Rowe, J.H., Garcia-de-Alba, C., Kim, C.F., Sharpe, A.H., and Haigis, M. C. (2021). The aging lung: physiology, disease, and immunity. Cell 184, 1990&#x2013;2019.</Citation><ArticleIdList><ArticleId IdType="pubmed">33811810</ArticleId><ArticleId IdType="pmc">8052295</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2021.03.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz, A.R., Fiebig, L., Hirseland, H., Diekmann, L.M., Reinke, S., Hardt, S., Niedobitek, A., and Mei, H.E. (2023). SARS-CoV-2 specific plasma cells acquire long-lived phenotypes in human bone marrow. eBioMedicine 95, 104735.</Citation><ArticleIdList><ArticleId IdType="pubmed">37556944</ArticleId><ArticleId IdType="pmc">10432952</ArticleId><ArticleId IdType="doi">10.1016/j.ebiom.2023.104735</ArticleId></ArticleIdList></Reference><Reference><Citation>Servellita, V., Syed, A.M., Morris, M.K., Brazer, N., Saldhi, P., Garcia-Knight, M., Sreekumar, B., Khalid, M.M., Ciling, A., Chen, P.Y., et al. (2022). Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants. Cell 185, 1539&#x2013;1548.e5.</Citation><ArticleIdList><ArticleId IdType="pubmed">35429436</ArticleId><ArticleId IdType="pmc">8930394</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2022.03.019</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw, Y.P., Hustek, S., Nguyen, N., Starlin, M., Wipfler, K., Wallace, B.I., and Michaud, K. (2022). Rheumatic disease patient decision-making about COVID-19 vaccination: a qualitative analysis. BMC Rheumatol 6, 76.</Citation><ArticleIdList><ArticleId IdType="pubmed">36443813</ArticleId><ArticleId IdType="pmc">9706890</ArticleId><ArticleId IdType="doi">10.1186/s41927-022-00307-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Shekerdemian, L.S., Mahmood, N.R., Wolfe, K.K., Riggs, B.J., Ross, C.E., McKiernan, C. A., Heidemann, S.M., Kleinman, L.C., Sen, A.I., Hall, M.W., et al. (2020). Characteristics and outcomes of children with coronavirus disease 2019 (COVID-19) infection admitted to US and Canadian Pediatric Intensive Care Units. JAMA Pediatr 174, 868&#x2013;873.</Citation><ArticleIdList><ArticleId IdType="pubmed">32392288</ArticleId><ArticleId IdType="doi">10.1001/jamapediatrics.2020.1948</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi, T., Pan, J., Vasileiou, E., Robertson, C., and Sheikh, A. (2022). Risk of serious COVID-19 outcomes among adults with asthma in Scotland: a national incident cohort study. Lancet Respir Med 10, 347&#x2013;354.</Citation><ArticleIdList><ArticleId IdType="pubmed">35033224</ArticleId><ArticleId IdType="pmc">8758152</ArticleId><ArticleId IdType="doi">10.1016/S2213-2600(21)00543-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Shields, A.M., Tadros, S., Al-Hakim, A., Nell, J.M., Lin, M.M.N., Chan, M., Goddard, S., Dempster, J., Dziadzio, M., Patel, S.Y., et al. (2022). Impact of vaccination on hospitalization and mortality from COVID-19 in patients with primary and secondary immunodeficiency: the United Kingdom experience. Front Immunol 13, 984376.</Citation><ArticleIdList><ArticleId IdType="pubmed">36211396</ArticleId><ArticleId IdType="pmc">9539662</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2022.984376</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegel, C.A., Melmed, G.Y., McGovern, D.P., Rai, V., Krammer, F., Rubin, D.T., Abreu, M.T., and Dubinsky, M.C. (2021). SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting. Gut 70, 635&#x2013;640.</Citation><ArticleIdList><ArticleId IdType="pubmed">33472895</ArticleId><ArticleId IdType="doi">10.1136/gutjnl-2020-324000</ArticleId></ArticleIdList></Reference><Reference><Citation>Signes-Costa, J., N&#xfa;&#xf1;ez-Gil, I.J., Soriano, J.B., Arroyo-Espliguero, R., Eid, C.M., Romero, R., Uribarri, A., Fernandez-Rozas, I., Aguado, M.G., Becerra-Munoz, V.M., et al. (2021). Prevalence and 30-day mortality in hospitalized patients with Covid-19 and prior lung diseases. Archivos de Bronconeumolog&#xed;a 57, 13&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">34629634</ArticleId><ArticleId IdType="doi">10.1016/j.arbres.2020.11.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon-Loriere, E., and Schwartz, O. (2022). Towards SARS-CoV-2 serotypes? Nat Rev Microbiol 20, 187&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">35181769</ArticleId><ArticleId IdType="pmc">8855751</ArticleId><ArticleId IdType="doi">10.1038/s41579-022-00708-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Skevaki, C., Chinthrajah, R.S., Fomina, D., Rohde, G., Cao, S., He, Z., Serdotetskova, S., Seidemann, C., Gr&#xfc;newaldt, A., Vengadeswaran, A., et al. (2023). Comorbidity defines asthmatic patients&#x2019; risk of COVID-19 hospitalization: a global perspective. J Allergy Clin Immunol 151, 110&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">36336123</ArticleId><ArticleId IdType="doi">10.1016/j.jaci.2022.09.039</ArticleId></ArticleIdList></Reference><Reference><Citation>Soresina, A., Moratto, D., Chiarini, M., Paolillo, C., Baresi, G., Foc&#xe0;, E., Bezzi, M., Baronio, B., Giacomelli, M., Badolato, R., et al. (2020). Two X-linked agammaglo-bulinemia patients develop pneumonia as COVID-19 manifestation but recover. Pediatr Allergy Immunol 31, 565&#x2013;569.</Citation><ArticleIdList><ArticleId IdType="pubmed">32319118</ArticleId><ArticleId IdType="pmc">7264678</ArticleId><ArticleId IdType="doi">10.1111/pai.13263</ArticleId></ArticleIdList></Reference><Reference><Citation>Southworth, T., Jackson, N., and Singh, D. (2022). Airway immune responses to COVID-19 vaccination in COPD patients and healthy subjects. Eur Respir J 60, 2200497.</Citation><ArticleIdList><ArticleId IdType="pubmed">35728975</ArticleId><ArticleId IdType="pmc">9403393</ArticleId><ArticleId IdType="doi">10.1183/13993003.00497-2022</ArticleId></ArticleIdList></Reference><Reference><Citation>Squire, J.D., and Joshi, A.Y. (2022). Response to mRNA COVID-19 vaccination in three XLA patients. Vaccine 40, 5299&#x2013;5301.</Citation><ArticleIdList><ArticleId IdType="pubmed">35934578</ArticleId><ArticleId IdType="pmc">9345887</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2022.07.046</ArticleId></ArticleIdList></Reference><Reference><Citation>Stock, S.J., Carruthers, J., Calvert, C., Denny, C., Donaghy, J., Goulding, A., Hopcroft, L.E.M., Hopkins, L., McLaughlin, T., Pan, J., et al. (2022). SARS-CoV-2 infection and COVID-19 vaccination rates in pregnant women in Scotland. Nat Med 28, 504&#x2013;512.</Citation><ArticleIdList><ArticleId IdType="pubmed">35027756</ArticleId><ArticleId IdType="pmc">8938271</ArticleId><ArticleId IdType="doi">10.1038/s41591-021-01666-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Stumpf, J., Schw&#xf6;bel, J., Lindner, T., Anders, L., Siepmann, T., Karger, C., H&#xfc;ther, J., Martin, H., M&#xfc;ller, P., Faulhaber-Walter, R., et al. (2022). Risk of strong antibody decline in dialysis and transplant patients after SARS-CoV-2mRNA vaccination: six months data from the observational Dia-Vacc study. Lancet Regional Health-Europe 17, 100371.</Citation><ArticleIdList><ArticleId IdType="pubmed">35434688</ArticleId><ArticleId IdType="pmc">8995854</ArticleId><ArticleId IdType="doi">10.1016/j.lanepe.2022.100371</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan, C.Y., Chiew, C.J., Pang, D., Lee, V.J., Ong, B., Wang, L.F., Ren, E.C., Lye, D.C., and Tan, K.B. (2023a). Effectiveness of bivalent mRNA vaccines against medically attended symptomatic SARS-CoV-2 infection and COVID-19-related hospital admission among SARS-CoV-2-naive and previously infected individuals: A retrospective cohort study. Lancet Infect Dis 23, 1343&#x2013;1348.</Citation><ArticleIdList><ArticleId IdType="pubmed">37543042</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(23)00373-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan, S.T., Kwan, A.T., Rodr&#xed;guez-Barraquer, I., Singer, B.J., Park, H.J., Lewnard, J.A., Sears, D., and Lo, N.C. (2023b). Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave. Nat Med 29, 358&#x2013;365.</Citation><ArticleIdList><ArticleId IdType="pubmed">36593393</ArticleId><ArticleId IdType="pmc">9974584</ArticleId><ArticleId IdType="doi">10.1038/s41591-022-02138-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang, J., Xu, Q., Zhu, C., Xuan, K., Li, T., Li, Q., Pang, X., Zha, Z., Li, J., Qiao, L., et al. (2024). Immunogenicity of tetravalent protein vaccine SCTV01E-2 against SARS-CoV-2 EG.5 subvaraint: a phase 2 trial. Vaccines 12, 175.</Citation><ArticleIdList><ArticleId IdType="pubmed">38400158</ArticleId><ArticleId IdType="pmc">10893468</ArticleId><ArticleId IdType="doi">10.3390/vaccines12020175</ArticleId></ArticleIdList></Reference><Reference><Citation>Tartof, S.Y., Slezak, J.M., Puzniak, L., Hong, V., Frankland, T.B., Ackerson, B.K., Xie, F., Takhar, H., Ogun, O.A., Simmons, S., et al. (2023). Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case-control study. Lancet Respir Med 11, 1089&#x2013;1100.</Citation><ArticleIdList><ArticleId IdType="pubmed">37898148</ArticleId><ArticleId IdType="doi">10.1016/S2213-2600(23)00306-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Taucher, C., Lazarus, R., Dellago, H., Maurer, G., Weisova, P., Corbic-Ramljak, I., Dubischar, K., Lilja, A., Eder-Lingelbach, S., Hochreiter, R., et al. (2023). Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): interim analysis of an open-label extension of the randomized, controlled, phase 3 COVCOMPARE trial. J Infect 87, 242&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">37406777</ArticleId><ArticleId IdType="doi">10.1016/j.jinf.2023.06.022</ArticleId></ArticleIdList></Reference><Reference><Citation>Bialek, S., Boundy, E., Bowen, V., Chow, N., Cohn, A., Dowling, N., Ellington, S., Gierke, R., Hall, A., MacNeil, J., et al. (2020). Severe outcomes among patients with coronavirus disease 2019 (COVID-19) &#x2014; United States, February 12&#x2013;March 16, 2020. MMWR Morb Mortal Wkly Rep 69, 343&#x2013;346.</Citation><ArticleIdList><ArticleId IdType="pmc">7725513</ArticleId><ArticleId IdType="doi">10.15585/mmwr.mm6912e2</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakkar, A., Gonzalez-Lugo, J.D., Goradia, N., Gali, R., Shapiro, L.C., Pradhan, K., Rahman, S., Kim, S.Y., Ko, B., Sica, R.A., et al. (2021). Seroconversion rates following COVID-19 vaccination among patients with cancer. Canc Cell 39, 1081&#x2013;1090.e2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2021.06.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Thanapluetiwong, S., Chansirikarnjana, S., Sriwannopas, O., Assavapokee, T., and Ittasakul, P. (2021). Factors associated with COVID-19 vaccine hesitancy in Thai Seniors. PPA Volume 15, 2389&#x2013;2403.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/PPA.S334757</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian, J., Yuan, X., Xiao, J., Zhong, Q., Yang, C., Liu, B., Cai, Y., Lu, Z., Wang, J., Wang, Y., et al. (2020). Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. Lancet Oncol 21, 893&#x2013;903.</Citation><ArticleIdList><ArticleId IdType="pubmed">32479790</ArticleId><ArticleId IdType="pmc">7259911</ArticleId><ArticleId IdType="doi">10.1016/S1470-2045(20)30309-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner, J.S., Kim, W., Kalaidina, E., Goss, C.W., Rauseo, A.M., Schmitz, A.J., Hansen, L., Haile, A., Klebert, M.K., Pusic, I., et al. (2021). SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans. Nature 595, 421&#x2013;425.</Citation><ArticleIdList><ArticleId IdType="pubmed">34030176</ArticleId><ArticleId IdType="doi">10.1038/s41586-021-03647-4</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Klaauw, A.A., Horner, E.C., Pereyra-Gerber, P., Agrawal, U., Foster, W.S., Spencer, S., Vergese, B., Smith, M., Henning, E., Ramsay, I.D., et al. (2023). Accelerated waning of the humoral response to COVID-19 vaccines in obesity. Nat Med 29, 1146&#x2013;1154.</Citation><ArticleIdList><ArticleId IdType="pubmed">37169862</ArticleId><ArticleId IdType="pmc">10202802</ArticleId><ArticleId IdType="doi">10.1038/s41591-023-02343-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijenthira, A., Gong, I.Y., Fox, T.A., Booth, S., Cook, G., Fattizzo, B., Martin-Moro, F., Razanamahery, J., Riches, J.C., Zwicker, J., et al. (2020). Outcomes ofpatients with hematologic malignancies and COVID-19: A systematic review and meta-analysis of 3377 patients. Blood 136, 2881&#x2013;2892.</Citation><ArticleIdList><ArticleId IdType="pubmed">33113551</ArticleId><ArticleId IdType="pmc">7746126</ArticleId><ArticleId IdType="doi">10.1182/blood.2020008824</ArticleId></ArticleIdList></Reference><Reference><Citation>Villar, J., Soto Conti, C.P., Gunier, R.B., Ariff, S., Craik, R., Cavoretto, P.I., Rauch, S., Gandino, S., Nieto, R., Winsey, A., et al. (2023a). Pregnancy outcomes and vaccine effectiveness during the period of omicron as the variant of concern, INTERCOVID-2022: A multinational, observational study. Lancet 401, 447&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">36669520</ArticleId><ArticleId IdType="pmc">9910845</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(22)02467-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Virgilio, E., Trevisan, C., Abbatecola, A., Malara, A., Palmieri, A., Fedele, G., Stefanelli, P., Leone, P., Schiavoni, I., Maggi, S., et al. (2022). Diabetes affects antibody response to SARS-CoV-2 vaccination in older residents of long-term care facilities: data from the GeroCovid Vax study. Diabetes Care 45, 2935&#x2013;2942.</Citation><ArticleIdList><ArticleId IdType="pubmed">36201657</ArticleId><ArticleId IdType="doi">10.2337/dc22-1255</ArticleId></ArticleIdList></Reference><Reference><Citation>Voysey, M., Costa Clemens, S.A., Madhi, S.A., Weckx, L.Y., Folegatti, P.M., Aley, P.K., Angus, B., Baillie, V.L., Barnabas, S.L., Bhorat, Q.E., et al. (2021). Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet 397, 881&#x2013;891.</Citation><ArticleIdList><ArticleId IdType="pubmed">33617777</ArticleId><ArticleId IdType="pmc">7894131</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(21)00432-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Wadei, H.M., Gonwa, T.A., Leoni, J.C., Shah, S.Z., Aslam, N., and Speicher, L.L. (2021). COVID-19 infection in solid organ transplant recipients afterSARS-CoV-2 vaccination. Am J Transplant 21, 3496&#x2013;3499.</Citation><ArticleIdList><ArticleId IdType="pubmed">33890410</ArticleId><ArticleId IdType="doi">10.1111/ajt.16618</ArticleId></ArticleIdList></Reference><Reference><Citation>Waissengrin, B., Agbarya, A., Safadi, E., Padova, H., and Wolf, I. (2021). Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancertreated with immune checkpoint inhibitors. Lancet Oncol 22, 581&#x2013;583.</Citation><ArticleIdList><ArticleId IdType="pubmed">33812495</ArticleId><ArticleId IdType="pmc">8016402</ArticleId><ArticleId IdType="doi">10.1016/S1470-2045(21)00155-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter, E.B., Talaat, K.R., Sabharwal, C., Gurtman, A., Lockhart, S., Paulsen, G.C., Barnett, E.D., Munoz, F.M., Maldonado, Y., Pahud, B.A., et al. (2022). Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age. N Engl J Med 386, 35&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">34752019</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2116298</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, Q.Q., Berger, N.A., and Xu, R. (2021). Analyses of risk, racial disparity, and outcomes among US patients with cancer and COVID-19 infection. JAMA Oncol 7, 220&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pubmed">33300956</ArticleId><ArticleId IdType="doi">10.1001/jamaoncol.2020.6178</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, R., Huang, H., Yu, C., Sun, C., Ma, J., Kong, D., Lin, Y., Zhao, D., Zhou, S., Lu, J., et al. (2023). A spike-trimer protein-based tetravalent COVID-19 vaccine elicits enhanced breadth of neutralization against SARS-CoV-2 Omicron subvariants and other variants. Sci China Life Sci 66, 1818&#x2013;1830.</Citation><ArticleIdList><ArticleId IdType="pubmed">36598621</ArticleId><ArticleId IdType="doi">10.1007/s11427-022-2207-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, Y., Ren, X., Wang, Z., Feng, X., Li, M., and Liu, P. (2022). Receipt of inactivated COVID-19 vaccine had no adverse influence on embryo implantation, clinical pregnancy and miscarriage in early pregnancy. Sci China Life Sci 65, 2332&#x2013;2334.</Citation><ArticleIdList><ArticleId IdType="pubmed">35696015</ArticleId><ArticleId IdType="pmc">9189441</ArticleId><ArticleId IdType="doi">10.1007/s11427-022-2133-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Westmeier, J., Paniskaki, K., Karakose, Z., Werner, T., Sutter, K., Dolff, S., Overbeck, M., Limmer, A., Liu, J., Zheng, X., Brenner, T., Berger, M.M., Witzke, O., Trilling, M., Lu, M., Yang, D., Babel, N., Westhoff, T., Dittmer, U., and Zelinskyy, G. (2020). Impaired cytotoxic CD8(+) T cell response in elderly COVID-19 patients. mBio 11, e02243&#x2013;e02220.</Citation><ArticleIdList><ArticleId IdType="pubmed">32948688</ArticleId><ArticleId IdType="pmc">7502863</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson, E.J., Walker, A.J., Bhaskaran, K., Bacon, S., Bates, C., Morton, C.E., Curtis, H.J., Mehrkar, A., Evans, D., Inglesby, P., et al. (2020). Factors associated with COVID-19-related death using OpenSAFELY. Nature 584, 430&#x2013;436.</Citation><ArticleIdList><ArticleId IdType="pubmed">32640463</ArticleId><ArticleId IdType="pmc">7611074</ArticleId><ArticleId IdType="doi">10.1038/s41586-020-2521-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Woldemeskel, B.A., Karaba, A.H., Garliss, C.C., Beck, E.J., Wang, K.H., Laeyendecker, O., Cox, A.L., and Blankson, J.N. (2022). The BNT162b2 mRNA vaccine elicits robust humoral and cellular immune responses in people living with human immunodeficiency virus (HIV). Clin Infect Dis 74, 1268&#x2013;1270.</Citation><ArticleIdList><ArticleId IdType="pubmed">34293114</ArticleId><ArticleId IdType="doi">10.1093/cid/ciab648</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong, M.C.S., Wong, E.L.Y., Huang, J., Cheung, A.W.L., Law, K., Chong, M.K.C., Ng, R.W.Y., Lai, C.K.C., Boon, S.S., Lau, J.T.F., et al. (2021a). Acceptance of the COVID-19 vaccine based on the health belief model: a population-based survey in Hong Kong. Vaccine 39, 1148&#x2013;1156.</Citation><ArticleIdList><ArticleId IdType="pubmed">33461834</ArticleId><ArticleId IdType="pmc">7832076</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2020.12.083</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong, S.Y., Dixon, R., Martinez Pazos, V., Gnjatic, S., Colombel, J.F., Cadwell, K., Gold, S., Helmus, D., Neil, J.A., Sota, S., et al. (2021b). Serologic response to messenger RNA coronavirus disease 2019 vaccines in inflammatory bowel disease patients receiving biologic therapies. Gastroenterology 161, 715&#x2013;718.e4.</Citation><ArticleIdList><ArticleId IdType="pubmed">33887219</ArticleId><ArticleId IdType="doi">10.1053/j.gastro.2021.04.025</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie, Y., Liu, Y., and Liu, Y. (2022). The flare of rheumatic disease after SARS-CoV-2 vaccination: a review. Front Immunol 13, 919979.</Citation><ArticleIdList><ArticleId IdType="pubmed">35860285</ArticleId><ArticleId IdType="pmc">9289284</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2022.919979</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu, J.W., Wang, B.S., Gao, P., Huang, H.T., Wang, F.Y., Qiu, W., Zhang, Y.Y., Xu, Y., Gou, J.B., Yu, L.L., et al. (2024). Safety and immunogenicity of heterologous boosting with orally administered aerosolized bivalent adenovirus type-5 vectored COVID-19 vaccine and B.1.1.529 variant adenovirus type-5 vectored COVID-19 vaccine in adults 18 years and older: a randomized, double blinded, parallel controlled trial. Emerging Microbes Infects 13, 2281355.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2023.2281355</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamal, J.M., Appana, S., Wang, M., Leon-Novelo, L., Bakota, E., Ye, Y., Sharma, S., Morrison, A.C., Marko, D., Linder, S.H., et al. (2022). Trends and correlates of breakthrough infections with SARS-CoV-2. Front Public Health 10, 856532.</Citation><ArticleIdList><ArticleId IdType="pubmed">35619825</ArticleId><ArticleId IdType="pmc">9127615</ArticleId><ArticleId IdType="doi">10.3389/fpubh.2022.856532</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, X., Wang, Y., Liang, Z., Cui, T., Chen, D., Li, G., Xu, H., Liu, S., Zhong, N., Huang, W., et al. (2024). Immune escape of BA.2.86 is comparable to XBB subvariants from the plasma of BA.5- and BA.5-XBB-convalescent subpopulations. J Med Virol 96, e29417.</Citation><ArticleIdList><ArticleId IdType="pubmed">38258345</ArticleId><ArticleId IdType="doi">10.1002/jmv.29417</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye, X., Ma, T., Blais, J.E., Yan, V.K.C., Kang, W., Chui, C.S.L., Lai, F.T.T., Li, X., Wan, E.Y.F., Wong, C.K.H., et al. (2022). Association between BNT162b2 or CoronaVac COVID-19 vaccines and major adverse cardiovascular events among individuals with cardiovascular disease. Cardiovasc Res 118, 2329&#x2013;2338.</Citation><ArticleIdList><ArticleId IdType="pubmed">35732274</ArticleId><ArticleId IdType="pmc">9278175</ArticleId><ArticleId IdType="doi">10.1093/cvr/cvac068</ArticleId></ArticleIdList></Reference><Reference><Citation>Yisimayi, A., Song, W., Wang, J., Jian, F., Yu, Y., Chen, X., Xu, Y., Yang, S., Niu, X., Xiao, T., et al. (2024). Repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting. Nature 625, 148&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">37993710</ArticleId><ArticleId IdType="doi">10.1038/s41586-023-06753-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Yonker, L.M., Neilan, A.M., Bartsch, Y., Patel, A.B., Regan, J., Arya, P., Gootkind, E., Park, G., Hardcastle, M., St. John, A., et al. (2020). Pediatric severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): clinical presentation, infectivity, and immune responses. J Pediatr s 227, 45&#x2013;52.e5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpeds.2020.08.037</ArticleId></ArticleIdList></Reference><Reference><Citation>Zambrano, L.D., Ellington, S., Strid, P., Galang, R.R., Oduyebo, T., Tong, V.T., Woodworth, K.R., Nahabedian Iii, J.F., Azziz-Baumgartner, E., Gilboa, S.M., et al. (2020). Update: characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status &#x2014; United States, January 22&#x2013;October 3, 2020. MMWR Morb Mortal Wkly Rep 69, 1641&#x2013;1647.</Citation><ArticleIdList><ArticleId IdType="pubmed">33151921</ArticleId><ArticleId IdType="pmc">7643892</ArticleId><ArticleId IdType="doi">10.15585/mmwr.mm6944e3</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng, G., Wu, Q., Pan, H., Li, M., Yang, J., Wang, L., Wu, Z., Jiang, D., Deng, X., Chu, K., et al. (2022). Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: Interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. Lancet Infect Dis 22, 483&#x2013;495.</Citation><ArticleIdList><ArticleId IdType="pubmed">34890537</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(21)00681-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, M., Wu, J., Zhang, X., Hu, C.H., Zhao, Z.P., Li, C., Huang, Z.J., Zhou, M.G., and Wang, L.M. (2021a). Prevalence and control of hypertension in adults in China, 2018 (in Chinese). Zhonghua Liu Xing Bing Xue Za Zhi 42, 1780&#x2013;1789.</Citation><ArticleIdList><ArticleId IdType="pubmed">34814612</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, Y., Luo, M.T., Wu, Q., Wang, Y.X., Ma, X., Yan, G., Zhang, S.H., Chen, Y., Wan, N., Zhang, L., et al. (2023). Long-term and effective neutralization against omicron sublineages elicited by four platform COVID-19 vaccines as a booster dose. Cell Discov 9, 17.</Citation><ArticleIdList><ArticleId IdType="pubmed">36754955</ArticleId><ArticleId IdType="pmc">9907876</ArticleId><ArticleId IdType="doi">10.1038/s41421-023-00518-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, Y., Zeng, G., Pan, H., Li, C., Hu, Y., Chu, K., Han, W., Chen, Z., Tang, R., Yin, W., et al. (2021b). Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18&#x2013;59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis 21, 181&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pubmed">33217362</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(20)30843-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu, K.W. (2023). Why is it necessary to improve COVID-19 vaccination coverage in older people? How to improve the vaccination coverage? Hum Vaccin Immunother 19, 2229704.</Citation><ArticleIdList><ArticleId IdType="pubmed">37433429</ArticleId><ArticleId IdType="pmc">10337491</ArticleId><ArticleId IdType="doi">10.1080/21645515.2023.2229704</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmermann, P., and Curtis, N. (2020). Coronavirus infections in children including COVID-19. Pediatr Infect Dis J 39, 355&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">32310621</ArticleId><ArticleId IdType="pmc">7158880</ArticleId><ArticleId IdType="doi">10.1097/INF.0000000000002660</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>